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Abstract  
Background: South Africa has the highest prevalence of obesity in sub-Saharan Africa, 
particularly in Black women. This population is thus at a higher risk of developing obesity-
associated type 2 diabetes mellitus (T2DM) and its associated co-morbidities such as non-
healing wounds. Adipose tissue-derived mesenchymal stem cells (ADSCs) have been widely 
utilized in the treatment of chronic wounds, however, autologous stem cell therapies using 
endogenous ADSCs from T2DM patients have proven unsuccessful. Metabolic disorders such 
as T2DM are thus thought to compromise the functional capacity of mesenchymal stem cells . 
The underlying molecular mechanisms that contribute to the functional decline of 
mesenchymal stem cells is still unclear and it is not yet known at which stage of disease 
progression ADSCs become compromised. In this research study, it was hypothesised that the 
progressive worsening of chronic systemic inflammation during disease progression from 
obesity towards T2DM, contributes to the decline of ADSCs’ multifunctional properties. 
Methods: A total of forty-seven (n=47) reproductive aged (18-45 years) Black Xhosa women 
from peri-urban areas surrounding the Tygerberg hospital, were included in this study. 
Participants were subdivided into: a) healthy lean (n=10) (BMI ≤ 25 kg/m2); b) healthy obese 
(n=11) (BMI ≥ 30 kg/m2); c) obese metabolic syndrome (n=19) and d) previously diagnosed 
T2DM (n=7) groups.  Health, lifestyle and dietary questionnaires were completed by 
participants. Anthropometric measurements and a dual energy x-ray absorptiometry (DXA) 
scan were performed in order to assess body composition. Blood samples were collected in 
order to assess each participant’s metabolic- (fasting blood glucose, total cholesterol, HDL, 
LDL, triglycerides) and inflammatory (CRP, SDF-1α, IL-6, IL-8, IL-10, TNF-α, IFN-γ) 
profiles. To establish whether a relationship exists between systemic inflammation at different 
stages of disease progression and stem cell impairment, in vitro experiments were performed 
in which ADSCs (Poietics cell line) were exposed to participant-derived serum for a period of 
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48h. Changes in cellular viability (MTT-based assay), proliferation (BrdU) and migrat ion 
(wound healing assay) were assessed using standard tissue culture techniques.  
Results: Systemic inflammation was evident in the healthy obese (CRP 29.8 ± 8 pg/mL) and 
obese metabolic syndrome (CRP 50.8 ± 24 pg/mL) participants. Additionally, circulating levels 
of the anti-inflammatory cytokine IL-10, were significantly reduced in T2DM participants 
(0.42 ± 0.63 pg/mL) (p < 0.05) compared to the healthy lean and obese groups.  Due to 
individual variability within the different groups, there were no significant differences  
observed in circulating levels of IL-6, IL-8, TNF-α and IFN-γ. However, there was a significant 
correlation between circulating levels of IL-6 and the proliferation of ADSCs, particularly in 
the healthy lean (p < 0.01) and metabolic syndrome (p < 0.01) groups. Furthermore, serum 
levels of IL-8 significantly correlated with the migration of ADSCs (p < 0.01). Healthy lean 
participant serum had a mitogenic effect on ADSCs, which was not observed in the obese 
groups.  
Conclusion: This study demonstrated for the first time, that the disruption in the delicate 
systemic inflammatory balance as a result of obesity, regardless of metabolic syndrome, may 
have an adverse effect on the functional capacity of ADSCs.  
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Opsomming 
Agtergrond: Suid Afrika het die hoogste voorkoms van vetsug (obesiteit), veral in swart 
vrouens, van al die Afrika-lande suid van die Sahara. Hierdie populasie het dus ŉ hoë risiko 
om tipe II (insulien-weerstandige) diabetes mellitus (T2DM) en verwante sekondêre toestande 
soos kroniese wonde te ontwikkel. Vetweefsel afkomstige mesenchiem stam selle, word 
dikwels gebruik vir die behandeling van kroniese wonde, maar stamsel-terapie wat gebruik 
maak van  diabetiese pasiënte se eie stam selle (liggaamseie sel terapie), is onsuksesvol. Daar 
word vermoed dat metaboliese siektes soos T2DM die funksionering van vetweefsel-stamse lle 
(ADSCs) aantas, alhoewel dit nog nie duidelik is op watter stadium van die siekte dit gebeur 
nie. In hierdie navorsingstudie het ons die hipotese ondersoek dat die kroniese inflammasie wat 
gepaardgaan met vetsug en T2DM bydra tot die verswakte funksionering van ADSCs.  
Metodes: Altesaam sewe-en-veertig (n=47) vrouens tussen 18 en 45 jaar oud, woonagtig in die 
voorstedelike gebiede naby Tygerberg hospitaal, het aan die studie deelgeneem. Die 
deelnemers is in vier groepe verdeel: a) gesond en skraal (n=10) (liggaamsmassa- indeks (LMI) 
≤ 25 kg/m2); b) gesond, nie-diabeties maar vetsugtig (n=11) (LMI ≥ 30 kg/m2); c) vetsugtig 
met metaboliese sindroom (n=19) en d) reeds gediagnoseerde T2DM (n=7). Pasiënte het 
gesondheid-, leefstyl- en voedingsvraelyste voltooi. Antropometrie en ‘n “dual energy x-ray 
absorptiometry” (DXA) skandering is uitgevoer om die liggaamsamestelling te assesseer.  
Bloedmonsters is versamel om die metaboliese (vastende bloedsuiker, totale cholesterol, HDL, 
LDL, triglycerides) en inflammatoriese profiele (CRP, SDF-1α, IL-6, IL-8, IL-10, TNF-α en 
IFN-γ) van pasiënte te analiseer. Om die vas te stel of daar ŉ verwantskap bestaan tussen 
sistemiese inflammasie tydens die verskillende stadiums van siekte-progressie en ADSC 
beskadiging, is in vitro selkultuur eksperimente uitgevoer waarin ADSCs (Poetics sellyn) 
behandel is met die bloedsera van individuele deelnemers. Veranderinge in sel-
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lewensvatbaarheid (MTT toets), selverdeling (BrdU toets) en sel migrasie (as ŉ aanduiding van 
wondheling) is gemeet onder standaard selkultuur-kondisies. 
Resultate: Sistemiese inflammasie was duidelik waarneembaar in die gesond vetsugtige (CRP 
29± 8 pg/mL) en metaboliese sindroom vetsugtige (CRP 50.8 ± 24 pg/mL) groepe. 
Serumvlakke van die anti-inflammatoriese sitokien IL-10 was beduidend laer in T2DM 
deelnemers (0.42 ± 0.63 pg/mL) (p < 0.05). Serumvlakke van IL-6, IL-8, TNF-α en IFN-γ het 
gevarieer, as gevolg van individuele variasie in die deelnemers van die verskillende groepe. 
Betekenisvolle verband tussen IL-6 vlakke en sel-verdeling is waargeneem, veral in die gesond 
skraal (p < 0.01) en metaboliese sindroom (p < 0.01) groepe. ŉ Veband tussen serumvlakke 
van IL-8 en sel-migrasie, was ook duidelik. Die stimulerende effek van serum op selverdeling 
was afwesig in serum afkomstig van vetsugtige deelnemers.  
Gevolgtrekking: Hierdie studie is die eerste om te bewys dat die funksionering van vetweefse l-
stam selle negatief beïnvloed kan word deur vetsug-gedrewe versteurings in die delikate 
sistemiese inflammatoriese balans, onafhanklik van die metaboliese sindroom. 
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Chapter 1 
Introduction 
In societies that are burdened with an increased incidence of lifestyle related diseases (such as 
obesity-induced type 2 diabetes), there is a clear need for preventative interventions against 
disease progression. It is estimated that over 80% of deaths from lifestyle diseases worldwide 
occur in low- and middle-income countries (Abegunde et al., 2007; Holmes et al., 2010) and 
projections indicate that as a source of morbidity and mortality, lifestyle diseases will overtake 
infectious diseases by 2030 (Mathers & Loncar, 2006).  
The literature review (chapter 2) will discuss the prevalence of obesity in South Africa, and 
highlight the predictions that in 2030 over 140 million people in developing countries 
(including South Africa) will be suffering from obesity-induced type 2 diabetes mellitus 
(T2DM) and its associated secondary complications (such as non-healing wounds) (Wild et al., 
2004). The literature review will also discuss disease progression from obesity to metabolic 
syndrome and ultimately the development of T2DM with the focus on body composition and 
low-grade systemic inflammation. It is well known that individuals who eventually develop 
T2DM, display inflammatory characteristics long before developing clinical symptoms 
(Alexandraki et al., 2006; Pradhan et al., 2003; Freeman et al., 2002). The prominent role that 
inflammation plays in disease progression, taken together with the recent discovery that the 
pathogenesis of T2DM can be detrimental to the function of endogenous stem/progenitor cells 
(endothelial progenitor cells, hematopoietic stem cells, mesenchymal stem cells) (Fadini et al., 
2013; van de Vyver, 2017), suggests a potential link between systemic inflammation and the 
functional decline of stem cells.  
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The implications of long term disease-associated changes in the systemic (circulation) and 
localized stem cell niche environments are however ill defined and the resultant stem cell 
impairment could potentially be a contributing factor to the development of co-morbidit ies. 
Furthermore, autologous stem cell therapies performed using mesenchymal stem cells (MSCs) 
from diabetic patients have proven unsuccessful, despite numerous remarkable reviews of 
successful allogeneic stem cell therapy in the treatment of diabetic co-morbidities such as foot 
ulcers. 
The overall purpose of this research was thus to improve our understanding of the high 
sensitivity of stem/progenitor cells to the pathological micro-environment associated with 
T2DM, and to assess the relationship between lifestyle choices, systemic inflammation and the 
functional impairment of stem cells.  
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Chapter 2  
Literature Review  
The dynamic shift to urbanisation has had various implications on the lives of people globally, 
with an astounding increase in the prevalence of obesity and obesity-related co-morbidit ies 
(Kelly et al., 2008). According to the World Health Organisation (WHO), in 2014 over 500 
million people worldwide were considered obese (WHO World Health Statistics, 2014 
http://www.who.int/gho/publications/world_health_statistics/2014/en/), and it is predicted that 
by the year 2030, approximately 1 billion people will be affected by this lifestyle related 
disorder. In developing countries, such as those in Sub-Saharan Africa, despite the majority of 
people living in poverty and undernutrition, obesity has fast become an epidemic (Ng et al., 
2014), with the highest prevalence evident in South Africa (Micklesfield et al., 2013).  
In 2014, the World Health Organization (WHO) indicated that over 70% of South African 
females were overweight (body mass index: BMI > 25 kg/m2), with 37.3% of females being 
obese (BMI > 30 kg/m2) and at risk for the development of T2DM (Dalal et al., 2011). Obesity 
is however less pronounced in South African males (15.7%) than females. The growing obesity 
epidemic in South Africa can be attributed to numerous factors such as poor dietary habits, a 
sedentary lifestyle, genetics and gender-related socio-cultural norms (Okop et al., 2016; 
Puoane et al., 2002; Stephens et al., 2017). 
o Poor dietary habits: Increasingly busy lifestyles contribute to poor nutritional habits 
due to the inclination of people to eat ready-made foods (Parfitt et al., 2010; Puoane et 
al., 2002) with a high calorie content. In low-to-middle income countries (LMIC) like 
South Africa, there is furthermore an inverse relationship between socio-economic 
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status (SES) and obesity (Chantler et al., 2016; Egbujie et al., 2016). Whilst the 
traditional western idea that lifestyle and dietary habits influence weight gain remain 
true, SES is another major contributor to the obesity epidemic. This is partly because 
in LMICs, the food that is affordable to the majority of people, is often unhealthy, lacks 
real nutritional value and contain large amounts of saturated fats and starch which 
ultimately lead to weight gain (Okop et al., 2016).  
o Sedentary lifestyle: Low physical activity is another factor associated with weight gain 
(Blundell et al., 2017; Cassidy et al., 2017). Obesity is driven by an energy intake 
versus energy expenditure factor (Blundell et al., 2017), thus, a balance in the amount 
of physical activity and calories consumed is required to maintain a healthy BMI 
(Cassidy et al., 2017). Increased physical activity on its own, however, does not 
guarantee the prevention of obesity (Blundell et al., 2017; Dickie et al., 2014). 
Highlighting that increased physical activity as well as calorie restrictions, are 
necessary for weight management.  
o Socio-cultural norms: Following an investigation into the perception of body size, 
obesity threat and the willingness to lose weight, Okop et al. (2016) demonstrated that 
in Black South African cultures, being overweight is seen as a sign of happiness and 
wealth. Consequently, men desire overweight women because it creates the illusion of 
prosperity (Mbochi et al., 2012; Okop et al., 2016). It is thus not surprising that the 
prevalence of obesity is greater in Black South African women than in men (Keswell 
et al., 2016). 
These factors, together with the rapid urbanisation of developing countries, are thus 
contributing to a much higher proportional increase in the prevalence of obesity compared to 
developed countries (Kelly et al., 2008). This exacerbates the burden of disease (Kelly et al., 
2008), especially since obesity predisposes an individual to develop metabolic syndrome. 
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Metabolic syndrome is a group of risk factors (dyslipidaemia, hyperglycaemia, hypertens ion 
and a large waist-to-hip ratio) (Xu et al., 2003), which increases an individual’s risk for 
developing non-communicable diseases (NCDs) such as cardiovascular disease (CVD), non-
alcoholic fatty liver disease, stroke and insulin resistant T2DM (Grundy, 2004; Ritchie & 
Connell, 2007). Globally, NCDs account for about 65% of all deaths and in developing 
countries, NCDs are responsible for 80% of deaths (Keswell et al., 2016). Type 2 diabetes in 
particular is associated with numerous co-morbidities, and given the increasing burden of 
disease, a better understanding of the molecular mechanisms underlying disease progression 
can aid prevention and treatment strategies.  
2.1. Disease progression: Obesity → Metabolic syndrome → T2DM 
2.1.1. Ethnic variations in body composition and the role of adipose tissue depots in the 
development of insulin resistance   
There are two main types of adipose tissue in the human body: brown adipose tissue (abundant 
in infants, heat producing function) and white adipose tissue (function as fat storage) 
(Nedergaard et al., 2007; Wensveen et al., 2015). White adipose tissue (WAT) is characterized 
by adipocytes with a single large lipid storage vesicle and may be distributed throughout the 
body at multiple visceral and subcutaneous locations. WAT provides plentiful capacity for 
storage of lipids, in the form of triglycerides (Ahmadian et al., 2007) and can be further 
subdivided depending on its location, type of precursor cells from which it originated and/or 
its metabolic profile (Sanchez-Gurmaches & Guertin, 2014). Visceral white adipose tissue 
(VAT) is located around internal organs and in abundance as central abdominal fat, whereas 
the peripheral fat located around the gluteo-femoral region is known as subcutaneous white 
adipose tissue (SAT). Numerous studies conducted to elucidate the role of different adipose 
tissue depots, suggest that not all fat stores contribute equally towards the development of 
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metabolic complications (Goedecke et al., 2009; Goedecke et al., 2011; Hanley et al., 2007; 
Keswell et al., 2016; Sanchez-Gurmaches & Guertin, 2014; Ritchie & Connell, 2007). The 
topic of whether all adipose tissue stores play a role in the development of metabolic syndrome, 
has however been controversial.  
For years, researchers thought that VAT is more closely associated with the development of 
metabolic syndrome. This was based on evidence from studies conducted on Caucasian 
participants, showing that VAT in obese individuals is a predominant source of chronic 
systemic inflammation, which is associated with metabolic diseases (Brochu et al., 2000; Ross 
et al., 2002; Weisberg et al. 2003; Hayashi et al., 2008) (refer to section 2.1.2, pg. 24). Hence, 
indices of VAT such as the threshold for waist circumference or waist-to-hip ratio (WHR) have 
been used as the gold standard to identify high risk individuals who are more prone to metabolic 
diseases. However, it is now known that ethnic variations exist in the relationship between 
waist circumference, VAT, and the development of metabolic diseases (Caroll et al., 2008; 
Considine et al., 2008; Deboer, 2010; Evans et al., 2011; Hamdy et al., 2006; Hayes et al., 
2013; Lovejoy et al., 1996).  
Numerous studies (refer to Table 2.1, pg. 22 - 23) have demonstrated that BMI and WHR do 
not accurately reflect VAT in Black women and that Black women have more peripheral SAT 
than VAT in the abdominal region, compared to Caucasian women of the same BMI (Carroll 
et al. 2008, Hayes et al., 2013, Keswell et al., 2016). From the table (Table 2.1, pg. 22 - 23) it 
is clear that despite differences in body composition and less central fat mass, similar levels of 
insulin resistance were evident in Black and Caucasian women. Goedecke et al. (2009) 
furthermore showed that deep SAT is closely, if not equally associated with the development 
of metabolic syndrome in Black South African (SA) women. 
SAT consists of the superficial SAT (subcutaneous layer in gluteal- femoral regions) as well as 
deep SAT (a third layer of adipocytes), which are histologically distinct and differ in metabolic 
Stellenbosch University  https://scholar.sun.ac.za
 22 
 
processes, with the deep SAT being more metabolically active (Brochu et al., 2000; Lundbom 
et al., 2013). Deep SAT has a protein profile which closely resembles that of VAT (known to 
be associated with metabolic syndrome) and may thus contribute to insulin resistance (Walker 
et al., 2007). Walker et al. (2007) made use of adipose tissue biopsies from healthy men (n=3) 
and women (n=7) to investigate the difference in adipokine expression between superfic ia l 
SAT, deep SAT and VAT. The overall results suggested that deep SAT displayed an 
independent association to the development of insulin resistance through its close resemblance 
to the protein profile observed in VAT (Walker et al., 2007). These findings are supported by 
an earlier study by Lovejoy et al. (2001), in which the authors highlighted the need to 
distinguish between the superficial SAT and deep SAT in terms of their relationship to 
metabolic risk factors. 
Table 2.1. Ethnic variations in fat distribution and their association with the development of metabol ic 
syndrome 
Author(s) Population Studied Findings 
Lovejoy et al., 1996 African-American  (n=37) and 
Caucasian (n=22) women 
African-American women are more 
insulin resistant than Caucasian 
counterparts and have less VAT.  
van der Merwe et al., 1998 Black (n=10) and Caucasian 
(n=10) South African women 
Caucasian women have significantly 
more VAT compared to Black women; 
more plasma insulin and circulating 
FFA.  
Lovejoy et al., 2001 African-American (n=55) and 
Caucasian (n=103) women 
African-American women have larger 
SAT depots, compared to Caucasian 
women. DSAT and VAT strongly 
correlates with metabolic risk factors.  
Ferris et al., 2005 Indian (female n=24, male n=19), 
Caucasian (female n=22, male 
n=19) and Black (female n=19, 
male n=8) subjects 
Black individuals had smaller WHR 
compared to Indian and Caucasian 
individuals. White individuals had higher 
serum adiponectin levels than Black and 
Indian individuals. 
Hanley et al., 2007 African-American (female n=299, 
male n=223) and Hispanic 
(female n=662, male n=452) 
individuals 
There is a stronger inverse association of 
VAT with adiponectin levels among 
African-American compared to Hispanic 
individuals. Age; female gender; HDL 
and SI were significant positive 
correlates of adiponectin in both 
ethnicities. 
Continued on next page 
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Author(s) Population Studied Findings  
Lee et al., 2006 African-American (female n=42, 
male n=41) and Caucasian 
(female n=37; male n=41) youth 
African American youth have 
significantly lower adiponectin levels, 
less VAT and are less insulin sensitive 
compared to their Caucasian 
counterparts. 
Carroll et al., 2008 African-American (female n=45, 
male n=21), Caucasian (female 
n=32, male n=15), Hispanic 
(female n=52, male n=20) 
African-American women have higher 
overall body fat percentage compared to 
Hispanic and Caucasian women as well 
as lower VAT, despite similar BMI and 
WHR.  
Goedecke et al., 2009 Black (n=26) and Caucasian 
(n=28) South African women 
Black women are more insulin resis tant; 
have less VAT than Caucasian women. 
Insulin resistance is associated with deep 
SAT in both Black and Caucasian 
women, but with only VAT in Caucasian 
women. 
Goedecke et al., 2011 Black (n=28) and Caucasian 
(n=26) South African women 
Black women have less VAT; SI and 
lipogenic and adipogenic genes in their 
SAT than Caucasian women. SI 
correlated with adipogenic genes 
expression. 
Gardener et al., 2013 African-American (female n=481, 
male n=225), Caucasian (female 
n=356, male n=228), Hispanic 
(female n=975, male n=570) 
Adiponectin levels are higher in 
Caucasian individuals than in African 
American and Hispanic individuals. 
Obesity is more strongly associated with 
adiponectin levels in African American 
individuals. 
Hayes et al., 2013 Black (n=28) and Caucasian 
(n=26) South African women 
Black women are more insulin resistant. 
DSAT & SSAT is associated with 
decreased insulin sensitivity in both 
ethnicities, but only with VAT in 
Caucasian women.  
Goedecke et al., 2013 Black (n=28) and Caucasian 
(n=26) South African women 
Caucasian women have more VAT; are 
more insulin sensitive and have elevated 
levels of GRα mRNA in SAT depots.  
Keswell et al., 2016 Black (n=288) and Caucasian 
(n=197) South African women 
Black women have more total body fat; 
less central fat and more lower-body fat 
than Caucasian women. There are ethnic 
differences associated with increased risk 
of CVDs.  
Footnote: Included in the table are studies conducted in South Africa and the United States of America, demonstrating the 
differences in fat distribution and type of fat prevalent in Black and Caucasian women, as well as how these relate to the 
development of metabolic syndrome. Abbr.: CVD – cardiovascular diseases; DSAT – deep subcutaneous adipose tissue; FFA – 
free fatty acid; GRα – glucocorticoid receptor alpha; SA – South Africa; SI – insulin sensitivity index; SSAT – superficial 
subcutaneous adipose tissue; WHR – waist-to-hip ratio; VAT – visceral adipose tissue. 
Continued from previous page 
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2.1.2. The relationship between metabolic dysregulation, chronic systemic inflammation and 
the progression of metabolic syndrome towards T2DM  
Adipocytes secrete adipokines (proteins with  paracrine/autocrine or endocrine functions) such 
as leptin and adiponectin, these factors contribute to metabolic regulation and insulin sensitivity 
(Hoffstedt et al., 2004; Scherer, 2006). Leptin, which functions as a satiety hormone under 
normal conditions (King et al., 2010), is significantly elevated in obese individuals and has 
been shown to be positively correlated with the hypertrophy of adipocytes (Weisberg et al., 
2003). Circulating leptin levels are thus often used as an indicator of adipose tissue mass 
(Johnson et al., 2012). Chronic elevation in leptin levels results in leptin resistance causing 
distortion of appetite regulation, which in turn exacerbates obesity (Johnson et al., 2012). 
Leptin also functions to regulate insulin secretion, which in extreme obesity, contributes to the 
development of insulin resistance (Osegbe et al., 2016). It is hypothesized that the increased 
levels of leptin lead to impaired regulation of the adipocyte-insulin axis in pancreatic beta cells 
causing hyperinsulinemia and ultimately insulin resistance (Osegbe et al., 2016). 
In contrast to leptin, adiponectin (role in modulation of glucose control and fatty acid oxidation) 
levels are significantly decreased in obese individuals and have a strong inverse relationship 
with the risk of developing metabolic syndrome (Duncan et al., 2004). This has been shown in 
both animal models and patient based studies (Choi et al., 2007; Yamauchi et al., 2001; Zhao 
et al., 2016). Insulin resistant mice have significantly decreased serum adiponectin levels 
compared to controls (Duncan et al., 2004), which is true for individuals who are insulin-
resistant. Furthermore, reductions in adiponectin production (within subcutaneous adipose 
tissue) is synonymous with decreased serum concentrations of the protein (Hoffstedt et al., 
2004). In the study by Hoffstedt et al. (2004) the authors demonstrated that in healthy obese 
(not insulin-resistant) individuals, despite reduced subcutaneous adipose tissue adiponectin 
production, no change in the serum concentration of the cytokine was observed. Another 
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interesting observation in this study was the significantly higher levels of adiponectin 
production observed in the healthy obese compared to the non-obese subjects, although serum 
concentrations were the same in these two groups. This suggested that serum adiponectin levels 
as well as adipose tissue production of adiponectin, are influenced by insulin sensitivity 
(Hoffstedt et al., 2004). The association between adiponectin levels and the development of 
insulin resistance, is however ethnically specific (Hanley et al., 2007; Considine et al., 2008). 
The ethnic variability in adiponectin levels is evident in studies demonstrating that normal 
weight African-American individuals have marginally lower levels of adiponectin compared 
to their Caucasian counterparts (Cohen et al., 2011; Gardener et al., 2013; Hanley et al., 2007).  
It has therefore been suggested that adiponectin levels might be more closely associated with 
insulin resistance in the Black population (Schutte et al., 2007) and might partially explain the 
higher prevalence of insulin resistance observed in this population.  
It is well known that insulin resistant obese individuals who eventually develop T2DM, display 
inflammatory characteristics long before developing the disease (Alexandraki et al., 2006; 
Freeman et al., 2002; Pradhan et al., 2003). There is an ongoing debate over whether the 
inflammation observed during obesity is due to macrophage infiltration into adipose tissue 
(Bourlier et al., 2008; Cancello et al., 2006; Curat et al., 2004 & 2006) or due to changes in 
the inflammatory secretory profile of adipocytes as a result of hypertrophy (reviewed by 
Cinkajzlová et al., 2017). Nonetheless, chronic low grade systemic inflammation is an 
independent risk factor for disease progression from obesity to metabolic syndrome and 
ultimately the development of T2DM (Christiansen et al., 2010).  
A persistent inflammatory environment such as that observed in extreme obesity results in an 
immune imbalance which is characterised by an accumulation of pro-inflammatory (classica lly 
activated M1) macrophages (Weisberg et al., 2003) and increased release of pro-inflammatory 
cytokines such as: C-reactive protein (CRP), interleukin 6 (IL-6) and tumour necrosis factor - 
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alpha (TNF-α). This inflammatory environment has deleterious effects at multiple sites in the 
body (Ritchie & Connell, 2007) and exacerbates insulin resistance (Rask-Madsen et al., 2003). 
Numerous studies have been conducted to elucidate the mechanism involved in ins ulin 
resistance, and TNF-α has consistently been shown to decrease insulin sensitivity by distorting 
insulin signalling at the receptor site (Rask-Madsen et al., 2003; Stagakis et al., 2012; 
Tangvarasittichai et al., 2016; Wang et al., 2015). In addition to contributing to the 
development of insulin resistance, chronic adipose tissue inflammation and excessive M1 type 
macrophage infiltration into adipose tissue are associated with a lack of adipocyte turnover 
(Barbagallo et al., 2017). Together these changes in the adipose tissue cellular composition 
(adipocyte hypertrophy followed by macrophage infiltration) and altered inflammatory 
cytokine expression at tissue level is considered a major cause of metabolic dysregulation and 
disease progression (Martyniak & Masternak, 2017). 
This shift in the inflammatory profile in response to adipocyte hypertrophy has been 
demonstrated in studies such as that of Briand et al. (2011). The authors used a diabetic rat 
(Zucker) model to show that in obese rats, an increase in adipocyte size is followed by a 
proportional increase in lipid droplet size, which in turn induce the expression of caveolin-1 
(Briand et al., 2011). The caveolin-1-dependent endothelium pathway has been shown to take 
part in the regulation of macrophage flow from the blood into adipose tissue (Ghigliotti et al., 
2014), which further demonstrates the role of caveolin-1 in accumulation of macrophages in 
the adipose tissue. In another study, Weisberg et al. (2003) demonstrated that the size of 
adipocytes is directly proportional to macrophage accumulation, by using 
immunohistochemical analyses of human subcutaneous adipose tissue. Kanda et al. (2006) 
furthermore demonstrated that the expression of chemokines such as the monocyte 
chemoattractant protein-1 (MCP-1/CCL2), which is largely produced by macrophages and 
endothelial cells, is increased in the adipose tissue of obese mice. This suggests that during 
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obesity-induced adipocyte hypertrophy, the expression of cytokines and chemokines by either 
adipocytes and/or macrophages drives the inflammatory response into a chronic state (refer to 
Fig. 2.1 and Table 2.2).  
From the table (Table 2.2, pg. 28) it is clear that the development of inflammatory disorders 
such as T2DM can be attributed to the shift in the cytokine profile to a pro-inflammatory state 
(Diaz-Flores et al., 2013). However, the exact mechanism in which these pro-inflammatory 
cytokines contribute to the development of T2DM is not yet fully understood. 
 
 
 
 
Figure 2.1. Adipose tissue hypertrophy triggers migration of innate and adaptive immune effector cells. The figure 
demonstrates how the increased size of adipocytes causes a cascade of events which trigger an immune response, resulting in the 
infiltration of pro-inflammatory cytokines (adapted from Ghigliotti et al., 2014).
Stellenbosch University  https://scholar.sun.ac.za
 28 
 
Table 2.2. Inflammatory cytokines and their association with metabolic syndrome and T2DM. 
Author(s) 
Purpose of 
study 
Inflammatory cytokines measured 
Baseline [control] Baseline [obese/MS/T2DM] Increased Decreased No change 
Esposito et al. (2003) intervention IL-6 (1.25 pg/mL), CRP (1.4 
pg/mL); IL-10 (1.2 pg/mL) 
IL-6 (3.08 pg/mL), CRP (5.8 pg/mL); 
IL-10 (2.45 pg/mL) 
- IL-6 (1.92 pg/mL); CRP 
(3.5 pg/mL); IL-10 (2.1 
pg/mL) 
- 
Hoffstedt et al. (2004) correlation  Adiponectin (13.5 ug/mL) Adiponectin (14 ug/mL) - - - 
Unek et al. (2010) correlation  hs-CRP (2.03 mg/L), sCD40L (0.44 
ng/mL) 
hs-CRP (4.48 mg/L), sCD40L (0.86 
ng/mL) 
- - - 
Derakhshan et al. (2012) correlation  SDF-1 (60 pg/mL) SDF-1 (205 pg/mL) 
 
- - 
Lucas et al. (2013) correlation  IL-6 (1.39 ng/L), IL-8 (1.83 ng/L), 
IL-10 (5.42 ng/L), TNF-α (1.77 
ng/L), GM-CSF (0.94 ng/L) 
IL-6 (2.61 ng/L), IL-8 (2.47 ng/L), 
IL-10 (8.58 ng/L), TNF-α (2.87 ng/L), 
GM-CSF (1.92 ng/L) 
- - - 
van Beek et al. (2014) correlation  IL-6 (0.43 pg/mL), IL-8 (8.4 
pg/mL), IL-10 (1.8 pg/mL), TNF-α 
(5.9 pg/mL), CRP (1.9 mg/L) 
IL-6 (1.62 pg/mL), IL-8 (8.2 pg/mL), 
IL-10 (3.0 pg/mL), TNF-α (7.6 
pg/mL), CRP (7.6 mg/L) 
- - - 
Al-Daghri et al. (2015) intervention - Adiponectin (0.82 ug/mL), CRP (40 
ng/mL), IL-6 (35.8 pg/mL), IL-10  
(28.4 pg/mL), TNF-α (91.5 pg/mL) 
Adiponectin (1.2 
ug/mL) 
CRP (20 ng/mL), IL-6  
(27.1 pg/mL), IL-10  
(21.1 pg/mL), TNF-α 
(79.4 pg/mL) 
 
Vargas et al. (2015) intervention CRP (19 mg/L) CRP (61 mg/L) - - 
 
Tangvarasittichai et al. 
(2016) 
correlation  TNF-α (2.78 pg/mL), IL-6 (1.65 
pg/mL), hsCRP (1.29 pg/mL) 
TNF-α (3.98 pg/mL), IL-6 (2.78 
pg/mL), hsCRP (2.41 pg/mL) 
   
Footnote: This table displays studies demonstrating the difference in serum circulating cytokines in obese, pre-diabetic and diabetic individuals compared to healthy lean women. Analysis was done on 
plasma or serum from patients. The increase/decrease refers to changes observed in the study subjects (obese/prediabetic/diabetic). Abbr.: hsCRP – C-reactive protein; IL – interleukins; MS – metabolic 
syndrome; T2DM – type 2 diabetic; TNF – tumour necrosis factor; SDF – stromal derived factor   
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The following sections will discuss some of the key cytokines involved in disease progression 
from obesity to metabolic syndrome and the development of T2DM. 
o C-Reactive Protein (CRP) 
Numerous studies that investigated the role of inflammation in the development of T2DM, 
particularly in women (refer to Table 2.2), have showed a strong correlation between increased 
levels of serum CRP and the development of T2DM (Freeman et al., 2002; Pradhan et al., 
2003; Castoldi et al., 2007; Unek et al., 2010). CRP is produced in the liver, leukocytes and 
adipose tissue, in response to increased levels of inflammatory cytokines (such as IL-6) 
(Tangvarasittichai et al., 2016) and is thought to play a role in the amplification of the 
inflammatory response (Unek et al., 2010). It is therefore defined as a biomarker of low-grade 
inflammation and has been implicated in metabolic diseases such as cardiovascular diseases 
(CVDs) and T2DM (Freeman et al., 2002; Han et al., 2002). In a study to determine whether 
CRP could be used as a predictor for the future development of T2DM, Freeman et al. (2002) 
recruited diabetic and non-diabetic middle-aged men and showed that high levels of CRP were 
associated with the development of T2DM, independent of established risk factors such as 
fasting plasma triglyceride, BMI, and glucose levels. Pradhan et al. (2003) conducted a similar 
study on middle-aged women, in order to investigate the association between insulin resistance, 
inflammation and an increased risk for the development of CVD and T2DM. The results 
confirmed that the correlation between serum CRP levels and the development of insulin 
resistance is independent of other metabolic risk factors (Chou et al., 2010; Lu et al., 2010; 
Pradhan et al., 2003). This supported the findings of Freeman et al. (2002) indicating that serum 
CRP levels can be used as a marker to predict the development of T2DM. Park et al. (2005) 
suggested that the association between CRP and insulin resistance might be linked to obesity. 
In the study by Park et al. (2005), the authors showed that serum CRP levels are correlated 
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with overall body mass (BMI) whilst IL-6 levels were more closely associated with visceral 
adiposity. 
o Interleukin-6 (IL-6) 
Research focussed on the association between CRP and inflammation have identified the 
cytokine IL-6 as a major role player in disease progression towards T2DM. IL-6 is a well-
known pro-inflammatory cytokine secreted by adipocytes and macrophages (Carey et al., 2004; 
Park et al., 2005) and is thought to be one of the main inducers of CRP production in the liver 
(Park et al., 2005). IL-6, much like CRP, is known to be elevated in obese individuals and has 
been linked to the development of T2DM. This was confirmed by Bertoni et al. (2010), who 
showed that elevated baseline serum IL-6 levels were a strong predictor for the incidence of 
T2DM in a multi-ethnic cohort over a period of 5 years. The same findings (elevated baseline 
serum IL-6) were later reported by Mirza et al. (2012) in both poorly controlled and well-
controlled diabetic patients. The association between IL-6 and the development of T2DM is 
thought to be through the upregulation of CRP production (Pradhan et al., 2003). There are 
however, some studies such as that of Hu et al. (2004), indicating that serum concentration of 
IL-6 is not as accurate as CRP when it comes to predicting T2DM. However, the unreliabi lity 
of IL-6 as a predictor is because it displays both pro- and anti-inflammatory characterist ics, 
due to a single nucleotide polymorphism in its promotor gene (Carey et al., 2004; Wang et al., 
2015) and its expression can be influenced by numerous acute inflammatory signals.  
o Tumour necrosis factor- alpha (TNF-α) 
TNF-α is overly expressed in obese individuals (Alexandraki et al., 2006) and plays a key role 
in the development of T2DM (Hu et al., 2004; Mirza et al., 2012; Rask-Madsen et al., 2003;) 
since it decreases insulin sensitivity by distorting insulin signalling at the receptor site (Rask-
Madsen et al., 2003). TNF-α furthermore has the functional capacity to influence the secretion 
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of other pro-inflammatory cytokines, and by doing so, amplifies the inflammatory response 
(Alexandraki et al., 2006; Kern et al., 2001). An imbalance of anti- and pro-inflammatory 
cytokines together with the environmental influences which result in a sustained inflammatory 
system, particularly in obesity, exacerbates disease progression (Wang et al., 2015).  
o Interleukin – 10 (IL-10) 
IL-10 is an anti-inflammatory cytokine that is largely produced by immune cells includ ing 
alternatively activated (M2) macrophages (van Exel et al., 2002) and functions to modulate 
inflammatory responses by suppressing synthesis of pro-inflammatory cytokines (Cassatella et 
al., 1993). In chronic inflammatory diseases such as T2DM, the balance between pro- and anti-
inflammatory cytokines is disrupted and as a consequence results in low levels of serum IL-10 
(Acharya et al., 2015; Al-Daghri et al., 2015; Pirola et al., 2017). Van Exel et al. (2002) 
conducted a study to determine the influence of a patient’s metabolic status on the ability of 
leukocytes to produce pro- (TNF-α) and anti-inflammatory (IL-10) cytokines. The authors 
assessed the cytokine production capacity in whole blood of T2DM patients after ex vivo 
stimulation with lipopolysaccharide (LPS) and observed a correlation between reduced IL-10 
production capacity and high plasma glucose and HbA1c levels. Furthermore, a correlation 
was observed between an increase in IL-10 production and a gradual decrease in the total 
cholesterol; LDL cholesterol; triglycerides; glucose and HbA1c levels (van Exel et al., 2002). 
TNF-α production had very little effect on the metabolic parameters of participants when IL-
10 production capacity was taken into account (van Exel et al., 2002). It has therefore been 
suggested that increased levels of serum IL-10 might have a protective effect against the 
development of T2DM and associated metabolic diseases by inhibiting the release of pro-
inflammatory cytokines (Cassatella et al., 1993; Esposito et al., 2003; Hong et al., 2009; Kelly 
et al., 2015).   
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2.2. The pathogenesis of T2DM and its influence on progenitor / stem cell 
mobilization and function 
Type 2 diabetes mellitus presents with numerous co-morbidities (including nephropathy, 
neuropathy, non-healing ulcers, and atherosclerosis) that occur as a consequence of 
pathological changes in the microenvironment that induce damage to various tissues and their 
microvascular network. Persistent hyperglycaemia in poorly controlled T2DM patients leads 
to the accumulation of advanced glycation end-products (AGEs) (Wang et al., 2015). AGEs 
are modified proteins which have been non-enzymatically glycated through the reduction of 
glucose with their amino group, thus initiating a complex series of rearrangements and 
hydrations (Kume et al., 2005; Serban et al., 2016; Unoki et al., 2007). On a cellular level, 
progenitor and stem cells are very susceptible to AGE-induced cellular damage (Basta et al., 
2002; Lu et al., 2012; Yang et al., 2010). The interaction between AGEs and their AGE-specific 
receptors (RAGEs) results in increased oxidative stress by inducing reactive oxygen species 
(ROS) production and activating the MAP kinase pathway, thus leading to downstream 
signalling activity through nuclear factor kappa B (NFκB) (Loeser et al., 2005; Madonna & De 
Catterina, 2011). Activation of NFκB by RAGE signalling, results in activation of the 
inflammatory pathway associated with diabetic osteoarthritis (Loeser et al., 2005). 
In the micro-vasculature system, the interaction between AGEs and their AGE-specific 
receptors (RAGEs) results in the upregulation of adhesion molecules (such as vascular cell 
adhesion molecule 1, VCAM1), allowing for the adhesion of activated inflammatory cells (M1 
macrophages) that in turn causes vascular stress (Schmidt et al., 1994). The repair of micro-
vascular damage is however compromised due to the lack of endothelial progenitor cell 
mobilization and function in the diabetic microenvironment (Fadini et al., 2013). These 
pathological changes in the microenvironment are furthermore known to cause remodelling of 
the bone marrow, affect the mobilization of mesenchymal stem cells (MSC) into peripheral 
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circulation and have detrimental effects on the regenerative function (maintenance of tissues) 
of these cells (Rezaie et al., 2017; van de Vyver, 2017).  
In healthy individuals, the mobilization of MSCs and endothelial progenitor cells is mediated 
by stromal derived factor – 1 alpha (SDF-1α) signalling (Li et al., 2016). This SDF-1α 
signalling axis is however disrupted in T2DM (Albiero et al., 2015; Karimabad et al., 2015) 
and differences in the serum SDF-1α concentrations is evident between healthy and T2DM 
patients (Derakhshan et al., 2012).  Derakhshan et al. (2012) compared the expression levels 
of SDF-1α in the serum of T2DM patients and control subjects and suggested that the 
significantly elevated levels of SDF-1α in diabetic patients might be associated with the 
aetiology of the disease. Based on previous reports, Derakhshan et al. (2012) suggested that 
the observed elevated levels of SDF-1α may occur in response to other pro-inflammatory 
cytokines (TNF-α, IFN-γ, IL-17) associated with T2DM (Arababadi et al., 2010; Hassanshahi 
et al., 2008) or as a compensatory mechanism in an attempt to induce mobilization of MSCs 
and endothelial progenitor cells (EPCs). Based on these findings, it was hypothesised that SDF-
1α may be a useful marker of the T2DM disease state and the likelihood for a patient to develop 
secondary complications.  
In another study, Ling et al. (2012) compared SDF-1α and vascular endothelial growth factor 
(VEGF) expression levels in T2DM and non-diabetic subjects following acute myocardia l 
infarction. Plasma levels of SDF-1α and VEGF peaked higher in diabetic patients compared to 
the non-diabetic subjects. The authors suggested that this peak in SDF-1α and VEGF levels 
may have been a protective mechanism by these cytokines, to recruit EPCs from the bone 
marrow, to facilitate the maintenance of myocardium integrity. However, circulating levels of 
EPCs were not proportional to the increase in these cytokines, suggesting a distortion in the 
signalling of the mobilization of EPCs in T2DM patients (Ling et al., 2012). This was also 
evident in a study by Butler et al. (2005) demonstrating that increasing levels of SDF-1α 
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corresponds to worsening disease complications, such as retinopathy. Their results showed a 
reduction in EPC recruitment with SDF-1α inhibition, which in turn prevented pre-retinal 
neovascularization leading to retinopathy. Taken together these studies indicate a strong 
association between elevated levels of SDF-1α and disease progression.  It is thus clear that 
impaired mobilization of stem/progenitor cells from the bone marrow contributes to the 
development of co-morbidities and that chronic exposure to pathological changes within the 
bone marrow microenvironment leads to dysfunction of these stem progenitor cells (refer to 
Table 2.3, pg. 35). 
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Table 2.3. Studies on the effect of inflammation and the pathogenesis of diabetes on endothelial progenitor 
and mesenchymal stem cell function. 
Author(s) Cell type Findings 
Possible mechanism  
Kume et al., 2005 Human MSCs 
AGEs reduce cell viability, decrease 
proliferation and differentiation capacity of 
MSCs 
AGEs induce MSC apoptosis through 
increased oxidation. 
Egan et al., 2008 Human PBMCs  
 Reduced expression of CXCR4 and 
CD34/CXCR4-positive cells is observed in 
PBMCs from diabetic patients. 
Diabetes impairs proliferation of EPCs 
as well as their mobilization 
Kang et al., 2009   
Decreased circulating levels of EPC due to 
suppressed mobilization following ischemia 
in a diabetic mice model 
Impaired EPC mobilization in diabetes 
is associated with altered HIF-1 
alpha/VEGF and MMP/TIMP 
regulation 
Fadini et al. 2010 Human EPCs 
Circulating levels of CD34+ are reduced in 
IFG, IGT and T2DM subjects 
Increased apoptosis and reduced 
mobilization due to hyperglycaemia.  
Prasanna et al., 2010 
Human MSCs, 
WJMSCs 
Pretreatment with IFN-y and TNF-α resulted 
in changes in morphology and growth 
characteristics of BMMSCs  
Increased inflammation distorts 
immodulatory properties of MSCs 
Stolzing et al., 2010 Rat MSCs 
Increased apoptosis, reduced cell viability and 
reduced bone formation observed in diabetic 
environment.  
AGEs induce oxidation resulting in 
apoptosis of MSCs. 
Lombardo et al., 
2012 
Human PBMCs, 
EPCs 
No significant difference in number of 
confirmed EPCs in T2DM and control 
subjects.  A reduced number of circulating 
EPCs was observed in T2DM, suggesting 
impaired mobilization of EPCs in T2DM.  
Hyperglycaemia results in impaired 
mobilization of EPCs. 
Lu et al., 2012 Human MSCs AGEs inhibit proliferation of MSCs in vitro. 
AGE-RAGE interaction inhibits SOD 
activity, resulting in increased ROS. 
Shin & Peterson, 
2012 
Mouse MSCs 
Prolonged diseases states impair the 
regenerative capacity of endogenous MSCs 
↓ expression of proliferat ive, 
angiogenic and differentiat ion 
signalling factors contribute to MSC 
dysfunction 
Fadini et al., 2013 Human EPCs 
BM stimulation with hrG-CSF results in 
increased circulating EPCs but only in non-
diabetic subjects 
G-CSF stimulates expression and 
activity of CD26/DPP4 resulting in 
degradation of SDF-1α. 
van de Vyver et al., 
2016 
Mouse MSCs 
Impaired wound closure was observed in 
MSCs from ob/ob mice  
Increased inflammation causes 
dysregulation of IL-6/STAT3 
signalling pathway which may be 
critical to MSC function  
Zeng et al., 2017 
Rat bone marrow 
derived EPCs 
AGEs induce EPC apoptosis. Lycopene 
improved EPC proliferation 
Lycopene reverses effects of AGE-
induced oxidation and thus improves 
EPC survival 
Footnote: The table above displays some of the studies which have demonstrated the effect of inflammation and T2DM on 
endothelial progenitor and mesenchymal stem cell function. Abbr.:  AGE – advanced glycation end products; BMMSC – bone 
marrow-derived mesenchymal stem cell; EPCs – endothelial progenitor cells; G-CSF- granulocyte – colony stimulating factor; 
IFG – impaired fasting glucose; IGT – impaired glucose tolerance;  MSCs – mesenchymal stem cells; ob/ob mice – transgenic 
mouse model of obesity; RAGE – receptor for advanced glycated end products, ROS – reactive oxygen species; SOD – 
superoxide dismutase 
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The dysfunction of endogenous bone marrow MSCs in diabetic patients has limited the success 
of autologous MSC therapies for the treatment of co-morbidities in these patients.   Adipose 
tissue-derived stem cells (ADSCs) do however have similar multi- functional properties to 
bone-marrow derived MSCs. Taken together with their abundant presence in adipose tissue 
and the relative ease of accessibility, ADSCs have thus become an attractive alternat ive 
therapeutic agent. However, the pathological microenvironment within adipose tissue has also 
been shown to modulate the behaviour of ADSCs (Pachón-Peña et al., 2016).  
2.2.1. The effect of metabolic dysregulation and inflammation on adipose tissue resident stem 
cells. 
ADSCs are multipotent cells capable of differentiating into any tissue of mesodermal lineage 
(i.e. adipose, bone, cartilage, skeletal muscle, cardiac muscle, endothelial, hematopoiet ic, 
pancreatic, and epithelial cell types) (Baglioni et al., 2009; Maharlooei et al., 2011) and share 
the multifunctional and immunomodulatory properties with bone marrow-derived MSCs 
(Ivanova-Todorova et al. 2009). They can be isolated from subcutaneous as well as visceral 
adipose tissue (Baglioni et al., 2009) and cultured under standard cell culture conditions (Zuk 
et al., 2001).  
The metabolic dysregulation of adipose tissue that lead to adipocyte hypertrophy, chronic 
adipose tissue inflammation and the formation of crown-like structures (excessive M1 pro-
inflammatory macrophage infiltration) has however been shown to limit the self-renewal 
capacity of ADSCs (Martyniak & Masternak, 2017).  ADSCs derived from diabetic patients 
are furthermore unable to differentiate into functional adipocytes in vitro (Barbagallo et al., 
2017), suggesting that metabolic and inflammatory changes within the localized tissue 
microenvironment impairs the function of ADSCs. It is however unclear at which stage of 
disease progression, ADSC function becomes compromised, since adipose tissue inflammation 
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is also thought to play a key role in governing the plasticity and differentiation of ADSCs 
(Badimon & Cubedo, 2017; Strong et al., 2015).  
It has been shown that low grade adipose tissue inflammation increases the size of the 
progenitor cell pool (Zhu et al., 2016) and the migration rate of ADSCs (Pachón- Peña et al., 
2016). This beneficial effect is however lost under conditions of long term chronic tissue 
inflammation, since metabolic syndrome negatively impacts the therapeutic potential of 
ADSCs (Oliva-Olivera et al., 2015). Oliva-Olivera et al. (2015) emphasized that the metabolic 
profile of patients should be taken into account when evaluating the reliability of ADSCs for 
therapeutic use. In their study, the authors demonstrated a decrease in the osteogenic potential 
of ADSCs in individuals with metabolic syndrome and that alterations occur in the 
transcriptional pattern of enzymes involved in cellular redox balance (Oliva-Olivera et al., 
2015), suggesting that slight changes within the gene expression profile of ADSCs may alter 
the therapeutic efficacy of these cells. This was confirmed in a study by Pachón-Peña et al. 
(2016) that compared the immunophenotypic profile of ADSCs derived from lean and obese 
individuals and investigated its association with ADSC plasticity. The authors indicated that in 
low oxygen tension conditions, increased proliferation and migration of ADSCs were only 
evident in cells derived from lean individuals. Furthermore, differences in proliferat ion, 
migration and differentiation capacity correlated with an altered immunophenotypic profile in 
ADSCs derived from obese individuals (Pachón-Peña et al., 2016; Yamamoto et al., 2013). 
Similarly, Ferrer-Lorente et al. (2014) demonstrated that ADSCs isolated from the 
subcutaneous adipose tissue of diabetic rats had reduced viability, proliferation and an impaired 
potential to differentiate into endothelial cells (ECs). Disruption of the delicately balanced 
inflammatory status of the adipose tissue can thus influence the multifunctional properties of 
ADSCs. It is however unclear whether systemic factors also contribute to the functional decline 
of ADSCs or if it is limited to changes in the localized tissue environment.   
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Chapter 3 
Aims and Objectives 
We hypothesized that the inflammatory changes in the systemic microenvironment observed 
during disease progression from obesity to type 2 diabetes mellitus (T2DM), can affect the 
viability, proliferation and migration capacity of adipose-derived mesenchymal stem cells 
(ADSCs). In order to test this hypothesis, we therefore (i) determined the inflammatory and 
metabolic profile of healthy lean-, healthy obese-, obese metabolic syndrome- and T2DM 
patients; (ii) used the patient-derived serum to treat a human ADSC cell line and assessed 
subsequent changes in ADSC functional capacity.  
AIM 1 
Participant (reproductive aged Black Xhosa females) recruitment and detailed assessment of 
the medical history, body composition and lifestyle of the participants.  
Objectives 
i) Collect serum (blood samples) from Black Xhosa reproductive aged females (n=47) 
who are either healthy lean, healthy obese, obese metabolic syndrome or obese type 2 
diabetic.  
ii) To have participants complete questionnaires in order to assess their medical history, 
nutritional and physical activity habits. 
iii)  To determine each participant’s body composition using Dual X-ray Absorptiometry 
(DXA) and anthropometric measures.  
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AIM 2 
Determination of the inflammatory and metabolic profile of each participant. 
Objectives 
i) Analyse serum for biomarkers of inflammation using multi-plex bead-array technology 
and ELISA assays to quantify the concentration of 8 cytokines (IL-2, IL-4, IL-6, IL-8, 
IL-10, TNF-α, IFN-γ, SDF-1α, CRP) in each serum sample. 
ii) Perform serum lipid panel analyses to quantify the concentration of total cholesterol, 
high density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides in 
each serum sample.  
AIM 3 
Determination of the effect of each participant’s serum on the multi- functional ability of an 
adipose tissue derived stem cell line.  
Objectives 
i) To assess the effect of each participant’s serum on MSC viability, proliferation rate, 
migration capacity by using various cell culture techniques. 
ii) To determine if correlations exist between the inflammatory biomarkers and metabolic 
profile of each participant and the effect that the serum has on the functional abilit ies 
of ADSCs.  
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Chapter 4 
Methodology 
This research study was conducted according to the ethical norms and principles for research 
established by the Declaration of Helsinki, the South African Medical Research Council 
Guidelines as well as the guidelines for Ethical Research: Principles Structures and Processes 
2004 (Department of Health, South Africa). 
Ethical approval (N15/07/066) to conduct this study, was attained from the Health Research 
Ethics Committee (HREC) of Stellenbosch University. HREC is registered with the South 
African Department of Health's National Health Research Ethics Council (NHREC) and with 
the US Office for human Research Protections (OHRP). Federal-Wide Assurance (FWA) 
numbers FWA00001372 IRB numbers IRB00005239 and IRB00005240. The HREC therefore 
complies with the South African National Health Act No. 61 2003 as it pertains to health 
research and the United States Code of Federal Regulation Title 45 Part 46.  
Permission to conduct research at the Tygerberg hospital was granted by the Western Cape 
Department of Health (National Health Research Database Project: WC2016RP14858) in 
accordance with the Provincial Research Policy and Tygerberg Hospital Notice No 40/2009.  
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This non-interventional human study consisted of three phases that were performed over a 
period of 24 months. The flowchart below gives an overview of the study design that will be 
discussed in more detail throughout this chapter. 
 
 
 
 
 
 
Figure 4.1. Overview of study design. Phase 1: Black Xhosa women were recruited into three groups; healthy lean, non-diabetic 
obese and previously diagnosed type 2 diabetes mellitus (T2DM) groups. The non-diabetic group was further subdivided into 
healthy obese and obese metabolic syndrome groups. Participants’ metabolic profiles were determined and blood samples were 
collected. Phase 3: Participant derived serum was used to treat adipose tissue-derived mesenchymal stem cells (ADSCs) in order 
to investigate its effect on the multifunctional properties of ADSCs. 
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4.1. PHASE 1: Participant recruitment, clinical data collection and 
subdivision of cohorts 
4.1.1. Participant recruitment 
Reproductive aged (18 - 45 years), Black South African women of Xhosa ancestry (n=47) were 
recruited via flyers or word-of-mouth, from peri-urban areas surrounding the Tygerberg tertiary 
hospital in Cape Town, Western Cape. Participation in the study was completely voluntary and 
participants were required to sign an informed consent form (Appendix A, pg. 96) before 
inclusion in the study.  
The following inclusion/exclusion criteria were used to recruit participants into specific groups: 
o Healthy lean group (n=10): Inclusion criteria: Black Xhosa women; aged 18 - 45 
years; body mass index (BMI) ≤ 25 kg/m2; normal fasting glucose level (< 5.6 mmol/L).  
o Obese non-diabetic group (n=30): Inclusion criteria: Black Xhosa women; aged 18 - 
45 years; BMI ≥ 30 kg/m2. 
o Obese type 2 diabetic group (n=7): Inclusion criteria: Black Xhosa women; aged 18 
- 45 years; BMI ≥ 30 kg/m2, previously diagnosed with type 2 diabetes mellitus.  
Exclusion criteria 
o Men 
o Women who are pregnant or breastfeeding 
o Women who suffer from any inflammatory disorders and/or infectious disease 
including HIV  
Note: Following the clinical screening of participants the obese non-diabetic group (n=30) 
were further subdivided into a healthy obese (n=11) and metabolic syndrome (n=19) group. 
Refer to Chapter 5 (pg. 61) for detailed description of metabolic criteria used for the subdivis ion 
of this cohort.  
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The target study population was chosen based on unpublished observational data from the 
Endocrinology ward at Tygerberg hospital suggesting an increased incidence of type 2 diabetes 
mellitus (T2DM) in Black South African women.  This observation is supported by Goedecke 
et al., (2013) demonstrating a higher prevalence of insulin resistance in Black South African 
women, indicative of a higher risk for the development of T2DM. 
4.1.1.1. Clinical screening  
Participants arrived at the Tygerberg hospital Endocrinology ward (A10) after a fasting period 
of at least 4 hours. Each participant was interviewed and a medical history, nutritional and 
lifestyle questionnaire completed (Appendix A, pg. 105). These questionnaires were compiled 
in collaboration with a dietician (Mrs L v Wyk, Tygerberg Hospital, Western Cape 
Government). The purpose of these questionnaires was to characterize our study population as 
well as to give an indication of their medical history.   
In addition to the questionnaires, the clinical screening included non-invasive anthropometr ica l 
and body compositions measures (section 4.1.1.2) to assess the extent of obesity, blood 
pressure measures (section 4.1.1.3) to screen for hypertension, fasting blood glucose measures 
(section 4.1.1.4) to screen for T2DM and serum lipid panel analysis (section 4.2.1) to screen 
for dyslipidaemia. 
4.1.1.2. Anthropometry and body composition 
The following non-invasive anthropometrical measures were performed: 
o Body mass index (BMI): Each participant’s weight (kg) (standard platform scale) and 
height (m) (portable stadiometer) were measured and their BMI calculated using the 
formula: BMI = total body weight (kg) / height squared (m2).  
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o Waist-to-hip ratio: Participants stood erect, arms at their sides, feet together and 
abdomen relaxed. A standard non-elastic measuring tape was used to measure the 
widest circumference of the buttocks (hip circumference) (cm) and the narrowest part 
between the umbilicus and the xiphoid process (waist circumference) (cm). This 
information was used to calculate the waist-to-hip ratio using the formula: waist 
circumference (cm)/hip circumference (cm).  
Each participants’ body composition was assessed using a Dual Energy X-ray 
Absorptiometry (DXA) scan (Hologic Discovery W, Serial Number 70215, Manufactured 
by Scientific Division of Hologic Inc, USA). The global DXA scan assessed the total bone 
mineral density (BMD), lean muscle mass as well as the percentage fat mass (%fat) and its 
distribution throughout specific body regions [left and right arms (Region 1); left and right 
legs (Region 2); trunk (Region 3); head (Region 4); android- (Region 5) and gynoid-  
(Region 6) regions] (Fig. 4.2).   
 
 
 
Figure 4.2. Body composition. A) Representative image of a study participant undergoing a DXA scan. B-C) Body composition 
comparison between a healthy lean (BMI ≤ 25) (B) and obese (BMI ≥ 30) (C) participant illustrating the different regions (R) on 
the DXA scanned images.  R1 – Arms; R2 – Legs; R3 – Trunk; R4 – Head; R5 – Android region; R6 – Gynoid region. Specific 
care was taken to analyse the same regions on each participant’s whole body scan. 
 
Stellenbosch University  https://scholar.sun.ac.za
 45 
 
4.1.1.3. Blood pressure 
While seated in a resting position, systolic and diastolic blood pressure levels were measured 
using a standard blood pressure measuring cuff and stethoscope (Aneroid Sphygmomanometer, 
HI-CARE int.). 
4.1.1.4. Fasting blood glucose 
Fasting blood glucose levels were measured using a Contour plus glucometer system (BAYER, 
Germany). Each participant’s finger was wiped with an alcohol swab to clear any dirt and 
debris before a small needle prick was made using a sterile lancet (Accu-chek; Roche, 
Germany). A drop of blood from the pricked finger was placed on a glucose measuring strip 
(Contour plus; BAYER, Germany) which was inserted into the glucometer. A reading between 
3.9 - 5.6 mmol/L was considered normal. In the event of a reading > 5.6 mmol/L, the test would 
be repeated and the participant was asked to disclose any food/beverage consumption prior to 
data collection in order to confirm fasting status.  
4.1.2. Blood sample collection and processing 
Qualified phlebotomists collected blood samples from the antecubital vein of participants, 
using PrecisionGlideTM Multi Sample Needles (BD Vacutainer®, USA). For each participant, 
blood was collected into one 10 mL Ethylenediaminetetraacetic acid (EDTA) vacutainer and 
three 5 mL serum separating (SS) tubes (SG Vac; BD, USA). 
o Blood samples collected in the SS tubes were allowed to clot before centrifuga tion 
(Eppendorf 5804; Sigma-Aldrich, Germany) at 3000 RPM for 10 minutes. Serum was 
aliquoted into 1.5 mL microfuge tubes (500 µl serum per tube) and stored at -80 °C 
until subsequent analyses.  
o Blood samples collected in the EDTA tubes were placed on ice immediately after 
collection, and used to determine each participant’s differential white blood cell count 
(WBC) using histological analysis of blood smears as described below. 
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 Four blood smears were prepared per participant: 1.5 to 2 µl of whole blood was pipetted onto 
each slide and an even smear created using a thin glass slide before leaving it to air dry for 1 
to 2 minutes. The blood smears were then fixed in methanol for 30 seconds, and once again 
allowed to air dry for approximately a minute. Crystal violet stain (1:1000) (Sigma-Aldr ich, 
Germany) was pipetted onto each slide (500 µl) and incubated at room temperature for 7 
minutes. After staining, slides were dabbed onto paper towels in a vertical position, rinsed in 
distilled water to remove excess stain and allowed to dry before mounting with a coverslip 
using DPX mounting media (Saarchem; Merck, SA). The stained blood smears were viewed 
under a microscope (Primovert; Zeiss, Germany) at 40x magnification and five random images 
taken (Canon EOS 1000D camera) per slide (Fig. 4.3). Images were analysed using ImageJ 
software (v 6.0, NIH, USA) and the total count of red and white blood cells recorded. Each 
image was loaded onto the ImageJ software and a grid with an area of 0.54 mm2 was overlaid 
onto the image. The total number of red blood cells (RBCs) were counted in 4 random squares 
on the grid for each image. The white blood cell (WBC) count for each participant were 
calculated as the average number of WBCs per 1000 RBCs. Different WBC subtypes were 
identified based on morphology according to a Basic Histology Text & Atlas (Junqueira & 
Carneiro, 2005). 
 
Figure 4.3. Representative image of a whole blood smear demonstrating the different blood cell types. A) Neutrophil. B) 
Basophil. C) Lymphocyte. D) Monocyte. E) Neutrophil. F) Red blood cell.  
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4.2. PHASE 2: Determination of each participants’ metabolic and 
inflammatory profile. 
4.2.1 Serum Lipid profile 
Serum was analysed using an automated lipid panel test cartridge (#10183107, Alere AfinionT M  
Lipid Panel; Alere, USA) in combination with the Afinion AS100 Analyzer (Alere, USA) (Fig. 
4.4). 
Principle of the analysis: Total cholesterol (mmol/L) and triglyceride levels (mmol/L) are 
measured by an enzymatic colorimetric method. Esterified and free cholesterol gets 
enzymatically converted into cholest-4-en-3-one and hydrogen peroxide which is used by 
hydrogen peroxidase to couple phenol and 4-aminoantipyrin to a red quinine-imine dye. 
Triglycerides are enzymatically converted into glycerol by lipoprotein lipase. Glycerol is then 
further catalysed in 2 steps to di-hydroxy-acetone-phosphate and hydrogen peroxide. The 
hydrogen peroxide reacts with 4-aminophenazone and 4-chlorophenol through peroxidase to 
form a red dyestuff. The colour intensity of these reactions is directly proportional to the 
concentration of triglycerides and cholesterol in the sample.  
To measure high density lipoprotein (HDL) (mmol/L); in a first reaction (R-1), anti-human 
apoliprotein B (apoB) antibody binds to apoB present on all lipoproteins except HDL (i.e. non-
HDL) (R-1). The antibody protects non-HDL from being degraded by pegylated cholesterol 
metabolizing enzymes in the second reaction (R-2). In R-2, free and esterified cholesterol of 
HDL are converted into cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide is 
used by peroxidase to couple 4-aminoantipyrin to F-DAOS and forms a blue colour complex 
of free and esterified HDL cholesterol.  
Low density lipoprotein (LDL) cholesterol is calculated using the Friedwald formula: LDL 
(mmol/L) = total cholesterol – HDL – triglycerides/2.2. 
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Figure 4.4. Alere Afinion Lipid Analyser. A) Lipid panel test cartridge with 1) capillary for sample loading and 2) reaction 
wells. B) Afinion AS100 Analyzer. 
4.2.2 Cytokine analyses 
4.2.2.1 Serum derived factor – 1 alpha (SDF-1 α)  
A Human ELISA kit (#0184080916; Thermo Scientific, USA) was used to determine serum 
SDF-1α concentrations according to the manufacturers’ instructions. Principle of the assay: 
samples are incubated with a pre-coated antibody (i.e. anti-SDF-1α). A streptavidin-HRP 
solution is added as the enzyme-linked antigen to detect presence of and bind to the antibody 
in the sample. Then a colourless substrate solution is added which produces a colour to indicate 
presence of antibody.   
✓ Serum was thawed on ice for approximately three hours prior to experiment and all 
reagents (provided in the kit) were brought to room temperature (RT).  
✓ Standards (serial dilutions: 0-6000 pg/mL) and serum samples were added to specific 
wells (in duplicates, i.e. n=2) in a pre-coated 96-well plate (100 µl per well) and 
incubated at RT for 2h 30 min on a platform shaker (Thermofisher, USA). Wells were 
washed four times with 300 µl 1X wash buffer per well, between steps. 
✓ Contents were discarded and 100 µl Streptavidin-HRP solution was added in each well 
and the plate incubated for 45 min at RT, on a platform shaker.  
✓ Contents were discarded and 100 µl TMB substrate solution (#H032916) was added 
per well and incubated for 30 min at RT on a platform shaker.  
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✓ When colour change was apparent, the plate was removed from platform shaker and 50 
µl Stop solution was added in each well.  
✓ Absorbance was read at 450 nm (constant 37 °C) using a standard spectrophotometer 
(Multiskan GO 1.00.40, Thermo-Scientific Group, USA).  
Results obtained from the spectrophotometer were exported into an Excel sheet and the linear 
regression model was used to generate a standard curve. The equation: 𝑦 = 𝑎𝑥 − 𝑐, with R2 = 
0.98, was used to calculate the concentration of each sample.  
4.2.2.2 C-Reactive Protein (CRP) 
A sandwich CRP Human ELISA kit (ab99995, Abcam, UK) was used to analyse serum 
according to manufacturer’s instructions. Principle of the assay:  Samples are added to wells 
that are pre-coated with a specific antibody (i.e. anti-CRP). The CRP present in the samples 
binds to the wells by the immobilized antibody. A biotinylated antibody HRP-conjugated 
Streptavidin is added to the wells to detect presence of antibody in samples. Then a TMB 
substrate solution is added to the wells and colour develops in proportion to the amount of CRP 
bound.  
✓ Samples were thawed on ice for 3 hours prior to use in the experiment and all reagents 
were brought to RT. Wells were washed four times with 300 µl 1X wash buffer per 
well, between steps. 
✓ 100 µl of each standard (serial dilutions ranging from 0-25 000 pg/mL) and sample 
were pipetted into specific wells in the pre-coated 96-well plate and incubated overnight 
in a 4 ◦C cold room, on a platform shaker. 
✓ The next morning, 100 µl of the 1X Biotinylated anti-Human CRP detector antibody 
was added in each well, after a washing. This was incubated for 1h at RT on a platform 
shaker. 
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✓ Solution was discarded and 100 µl 1X HRP-Streptavidin solution was added to each 
well and plate was incubated for 45 min at RT on a platform shaker.  
✓ The solution was discarded and 100 µl of TMB One-Step substrate reagent was added 
to each well and incubated at RT for 30 min, on a platform shaker.  
✓ Then 50 µl Stop Solution was added to each well and the absorbance read at 450 nm 
(Multiskan GO 1.00.40, THERMO-Scientific Group, USA). Results obtained from the 
reader were exported onto an excel sheet and a linear regression model was used to 
generate a standard curve. The equation 𝑦 = 𝑎𝑥2 − 𝑏𝑥 + 𝑐, with R2 = 0.99, was used 
to calculate the concentration of CRP in each serum sample.  
4.2.2.3 Bio-Plex ProTM Human Cytokine assay: IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α, 
GM-CSF 
A Bio-Plex Pro Human Cytokine 8-plex Assay kit (#M50000007A; Bio-Rad, USA) was used 
to assess the serum concentrations of interleukins; IL-2, IL-4, IL-6, IL-8, IL-10; interferon 
gamma (IFN-γ); tumour necrosis factor - alpha (TNF-α) and granulocyte macrophage - colony 
stimulating factor (GM-CSF). Principle of the analysis: The assay is a magnetic bead-based 
multiplex assay which uses an antibody directed against the desired targets that are covalently 
coupled to internally dyed beads. The assay was performed according to manufacturer’s 
instructions using reagents supplied in the kit.  
Serum samples were thawed on ice for approximately 2 hours prior to use in the assay and all 
reagents were brought to RT before use. The vial of assay standard stock was reconstituted 
with 500 µL Bio-Plex® sample diluent HB (Bio-Rad, USA). Table 4.1 displays the standard 
concentration ranges for each analyte. 
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Table 4.1. Normal physiological levels of group I human cytokines  and the standard concentration ranges 
of the 8-plex cytokine assay 
 
pg/mL 
Analyte 
Standard 
concentration range 
Expected normal 
physiological range 
GM-CSF 3.00 -  122 0.80 - 122 
IFN-γ 7.00 - 124 0.60 - 124 
IL-2 2.00 -90.0 0.60 - 124 
IL-4 0.06 - 3.00 0.01 - 3.00 
IL-6 0.50 - 9.00 0.02 - 9.00 
IL-8 0.40 -116 0.08 - 116 
IL-10 0.40 - 2.00 0.10 - 2.00 
TNF-α 6.00 - 98.0 0.10 - 98.0 
Footnote: Information derived from Bio-Plex suspension array system tech note 6029. Bio-Rad Laboratories, USA. 
✓ The diluted assay beads were vortexed for 20 seconds and 50 µl were added in each 
well in the 96-well assay plate and incubated at RT for 5 min without agitation.  
✓ Samples, standards and blanks were vortexed then 50 µl were added to specific wells. 
Plate was covered with foil and incubated at RT on platform shaker for 30 min. 
✓  25 µl detection antibody was added in each well and the plate incubated for another 30 
min on platform shaker.  
✓ 50 µl of 1X SA-PE were added to each well and plate incubated on platform shaker for 
10 min.  
✓ Assay beads were resuspended by adding 125 µl assay buffer in each well and plate 
was incubated on platform shaker for 30 seconds before analysis on the Luminex Bio-
Plex 200 System (Bio-Rad; USA) (Fig. 4.5A).  
Note: In between each of the above mentioned steps, the plate was washed twice with 100 µl 
1X wash buffer per well, using an automated wash station (Bio-PlexTM Pro Wash Station; Bio-
Rad, USA) (Fig. 4.5B).  
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Data were presented as the fluorescent intensity on the Bio-Plex ManagerTM software (Bio-
Rad, USA). The observed concentration of each target molecule was calculated from its 
fluorescent intensity based on the 5PL regression standard curve generated for each target.  
 
 
Figure 4.5. Bio-Rad Multiplex system. A) Luminex Bio-Plex 200 system. B) Bio-Plex Pro wash station. 
4.3. PHASE 3: Investigating the effect of serum factors on the 
multifunctional properties of adipose-derived mesenchymal stem cells 
All of the in vitro cell culture experiments (i.e. Phase 3 of the study) were performed using a 
primary human adipose-derived mesenchymal stem cell (hADSCs) line (Donor 26508, 
#000034977, Poeitics; Lonza, Switzerland). The initial 1 mL cryovial which was stored in 
liquid nitrogen, contained 1 x 106 immortalized hADSCs. The 1 mL ADSC cell stock (Passage 
0) was thawed quickly in a 37 °C warm water bath and the cell number expanded for the initia l 
passage at 1:20 dilution using cell culture dishes with 55 cm2 surface growth area. Cells were 
maintained in standard cell growth medium (SGM) at 37 °C, 5% CO2 and 90% humidity.  
SGM consisted of 90% Dulbecco’s Modified Eagle Medium (DMEM) with Ultraglutamine,  
containing 1% penicillin/streptomycin (pen/strep) (BioWhittaker; Lonza, Switzerland) and 
10% Fetal Bovine Serum (FBS) (Biochrom, Germany). SGM was replaced every 4 days and 
cells were sub-cultured at approximately 85% confluence. For the initial passage, cells from 
19 of the dishes were cryopreserved and cells from only one dish were further sub-cultured 
(passage 1).  
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Sub-culturing of cells: 
✓ At 85% confluence, cells were washed twice with 3 mL phosphate buffered saline 
(PBS) (Refer to Appendix C for detailed preparation of PBS).  
✓ 1 mL Trypsin (200mg/L Versene EDTA, #BE171616; Lonza, Belgium) was added in 
order to break down cell membrane integrity allowing for cells to detach from bottom 
of dish, then 2 mL SGM was added to stop Trypsin activity.   
✓ The cell suspension was added to a clean 15 mL conical tube (Falcon; BD, USA) and 
centrifuged at 1000 RPM (Eppendorf Centrifuge 5804; Sigma-Aldrich, USA) for 5 
minutes. The supernatant was discarded and cells were resuspended in 1 mL SGM.  
✓ 20 µl cell suspension was collected for cell counting. The cell suspension was added 
into the haemocytometer chamber, and viewed under a microscope (Primovert; Zeiss, 
Germany) at 40x magnification. Refer to Appendix C for a detailed description of the 
cell counting. Cells were further plated in new 100 mm culture dishes (55 cm2) 
containing 10 mL SGM, according to the recommended seeding density (Table 4.2) 
and incubated at 37 °C, 5% CO2 and 90% humidity. 
Freezing of cells: 
Cells were washed with PBS, trypsinized and centrifuged as previously described, then 
resuspended in 1 mL freezing media. Freezing media contained 10% dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich, Germany), 80% DMEM with Ultraglutamine (containing 1% 
pen/strep) and 10% FBS. Cells were stored in 1.5 mL cryogenic vials (Corning Inc., USA) at -
80 °C overnight, then at -196 °C in liquid nitrogen. Refer to Table 4.2 for the seeding density.  
Table 4.2. Recommended seeding densities according to culture insert diameters. 
Corning dishes/Transwell 
Insert format 
Approximate Growth 
Area (cm2) 
Seeding density 
(at 5 000 cells/cm2) 
Average Cell Yield 
100 mm 55 2.75 *105 5.5 * 106 
96 well 0.143 1.6 * 103 1.4 * 104 
24 well 0.33 9.5 * 103 3.3 * 104 
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4.3.1. Characterization of ADSC cell line using flow cytometry.  
Human adipose derived stem cells (ADSCs) (Donor 26508, #000034977, Poietics) were 
purchased from Poietics (Lonza; Basel, Switzerland). The ADSCs were obtained as 
lipoaspirates from patients undergoing elective liposuction surgery procedures and after 
purification, the phenotype characterization (CD13+, CD29+, CD44+, CD73+, CD90+, 
CD105+, CD166+ and CD14-, CD31-, CD45-) as well as quality control checks (HIV-, 
hepatitis B/C-, mycoplasma-free, bacteria-free, fungi- free, yeast-free) were performed by the 
manufacturer (Poietics; Lonza, Basel, Switzerland). The identity of the ADSCs were confirmed 
in our laboratory by using the MACS Miltenyi Biotech human MSC phenotyping kit (#130-
095-198; Miltenyi Biotech Inc., USA) and the FACS Calibur flow cytometer with CellQuest 
software (BD, USA). ADSCs (80% confluent, passage 7) were harvested through 
trypsinization and resuspended in PBS containing 20% FBS (Biochrom, Germany). Cell 
suspension at a concentration of 1x106 cells were co-labelled with a cocktail of fluorochrome-
conjugated monoclonal antibodies: Positive markers – CD90-FITC (clone DG3, isotype IgG1), 
CD73-APC (clone AD2, isotype IgG1), CD105-PE (clone 43AE1, isotype IgG1) and Negative 
markers - CD14-PerCP (clone TUK4, isotype IgG2a), CD20-PerCP (clone LT20.B4, isotype 
IgG1), CD34-PerCP (clone AC136, isotype IgG2a), CD45-PerCP (clone 5B1, isotype IgG2a) 
(Miltenyi Biotech Inc., Auburn, USA). Since a multicolour cytometric analysis was performed, 
fluorescent compensation settings were established through a compensation experiment and 
regions of positive and negative staining were determined through a fluorochrome minus one 
(FMO) experiment. An isotype control cocktail (IgG1-FITC/PE/APC/PerCP, clone IS5-21F5 
and IgG2a-PerCP, clone S43.10) (Miltenyi Biotech Inc., Auburn, USA) was used as a negative 
control for gating purposes. Data analysis was performed using Flow Jo Vx (Treestar, Oregon, 
USA) software. 
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Table 4.3. Acquisition settings on the FACS Calibur 
 
Detector V A Mode 
 
FSC E-1 4.75 Lin 
 
SSC 366 1.00 Lin 
FITC FL1 366 
 
Log 
PE FL2 327 
 
Log 
PerCP FL3 381 
 
Log 
APC FL4 463 
 
Log 
Footnote: The above acquisition settings were applied for the flow cytometric analyses. Abbr.: V – voltage; A – amperes.  
 
4.3.2. Treatment of ADSCs with participant derived serum 
Participant-derived serum was sterile filtered prior to use in experiments. Using a glass syringe, 
serum was filtered through a sterile filter (#14140003907; Cellulose Acetate Membrane, GVS, 
England, UK) into a clean 15 mL conical tube (Falcon; BD, USA). This was then used in 
treatment medium consisting of 20% participant-derived serum and 80% DMEM with 
Ultraglutamine (containing 1% pen/strep). The treatment medium was used in subsequent 
experiments to investigate the effects of participant-derived serum ADSC function.  
 
4.3.2.1. Cell proliferation assay 
The 5-bromo-2'-deoxyuridine (BrdU) proliferation assay was used to measure the mitogenic 
response of cultured ADSCs following exposure to participant-derived serum for a period of 
24-hours. All experiments were done in triplicate.  
For the initial experiment, standard cell culture growth media containing different 
concentrations (%) of FBS were used to determine coefficient of variance (CV) in order to 
validate our method and the reproducibility thereof.  
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Figure 4.6. BrdU proliferation assay. Graph showing results of the BrdU cell proliferation assay at different concentrations of 
serum in the growth medium. CV = 4.99 % 
ADSCs were cultured in a 96-well plate (refer to Table 4.2, pg. 53, for seeding density). SGM 
was added to make up a volume of 100 µL per well, these were incubated at 37 °C, 5% CO2 
and 90% humidity until ADSCs adhered to the bottom of the dish (approximately 5 hours). 
Once adhered, ADSCs were serum starved by removing all SGM from wells and adding 100 
µL cell media containing 1% FBS, in each well, and incubating overnight. The following day, 
the 1% SGM was discarded and new media was added into specific duplicate wells at 
concentrations of 1%, 5%, 10% and 15% FBS, respectively. These were incubated for 24 hours.  
A BrdU cell proliferation kit (#11417600, Roche; Switzerland) was utilised as per the 
manufacturer’s instructions. At 20 hours of incubation, 100 µL BrdU labelling reagent was 
added in each well and incubated for a further 4 hours. During this labelling period, the BrdU 
becomes incorporated into the DNA of proliferating cells which are then detected by the anti-
BrdU antibody. After 24 hours of incubation, media was removed and 200 µL FixDenat 
solution was added in each well and the plate was incubated for 30 minutes at room temperature  
without agitation. Solution was removed and 100 µL anti-BrdU-POD working solution was 
added to each well and the plate was then incubated for 90 minutes at RT. The antibody was 
removed and wells were washed three times with 300 µL washing solution. Then 100 µL 
Substrate solution was added in each well, the plate was covered with foil and incubated at RT 
for 12 minutes until colour developed. The plate was inserted into a spectrophotometer to 
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measure absorbance at 450 nm and 550 nm. Results obtained from the reader were exported 
onto an excel sheet and a graph was generated (Fig. 4.6).  
Subsequent experiments were performed using cell media containing 20% participant serum 
as treatment. 
4.3.2.2. Cell viability assay 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) In Vitro 
Toxicology assay kit (#SLBM0752V, Sigma-Aldrich; Germany) was used to measure cell 
viability. Principle of assay: The mitochondrial dehydrogenases of viable cells cleave the 
tetrazolium ring, yielding purple formazan crystals which can be dissolved in acidified 
isopropanol. The absorbance of the resulting purple solution is measured 
spectrophotometrically. An increase or decrease in cell number results in a concomitant change 
in the amount of formazan formed, indicating the degree of cytotoxicity caused by the test 
material.  
All experiments were repeated three times in duplicate wells. In the initial experiment, different 
concentrations (%) of FBS in standard cell culture media were used as treatment. This was in 
order to check the validity and reproducibility of our method.  
 
Figure 4.7. MTT In Vitro Toxicology assay. Graph showing results of the MTT in vitro Toxicology assay, using different 
concentrations of serum in the cell culture medium. Values obtained at the reference wavelength of 690 nm were subtracted from 
570 nm to produce the values represented on graph, to correct for any background absorbance.  
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Cells were cultured in a 96-well plate (refer to Table 4.2, pg. 53 for seeding density). SGM was 
added in each well to a total volume of 100 µL. Plates were incubated at 37 °C, 5% CO2 and 
90% humidity until 100 % confluence (7 days on average, with media change after 4 days). At 
100 % confluence, media was discarded and cell culture media containing 0.1%; 1%; 5%; 10% 
and 15% FBS were added to specific wells (100 µL) and plates were incubated for a further 24 
hours.  
A vial of 15 mg MTT (#MKBR4419V, Sigma-Aldrich, Germany) was reconstituted in 3 mL 
DMEM with Ultraglutamine (containing 1% pen/strep). After 20 hours of incubation, 10 µL 
reconstituted MTT reagent was added in each well and plates were incubated for further 4 
hours, for the formazan crystals to form. After the incubation period (24 hours in total), 100 
µL MTT solubilisation solution was added to each well and triturated with a pipette to dissolve 
the crystals. After approximately 5 minutes, the plate was inserted into a spectrophotometer to 
measure absorbance at wavelengths of 570 and 690 nm. Results from the spectrophotometer 
were exported into an excel sheet. Values obtained at 690 nm were subtracted from values at 
570 nm (to reduce background absorbance).  
Subsequent experiments were performed using cell media containing 20% participant derived 
serum as treatment.  
4.3.2.3. Cellular migration assay 
In order to investigate the effect of participant derived serum on the migration response of 
ADSCs, we performed a migration assay using 2 well µ-plates (ibidi, Germany). ADSCs were 
cultured at a seeding density of  ̴ 3.0 x 104 cells per well. 70 µL cell suspension was added to 
each of the wells/chambers of the µ-plate, the culture insert (Fig 4.8A) produced the in vitro 
wound (Fig. 4.8B) which is used to measure migration response. These were incubated at 37 
°C, 5% CO2 and 90% humidity overnight.  
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Figure 4.8. Migration assay. A) The ibidi 2 well µ-plate dish with culture insert intact. B) ADSCs as cultured in the µ-plate dish, 
after removal of culture insert, displaying the in vitro wound at 0 hours. 
The following morning, cells were 100% confluent and adhered to bottom of dish. The culture 
insert was removed using sterile tweezers. SGM was added and three random images were 
taken (EOS600D Canon digital camera) of the in vitro wounded area, at 0, 4, 7 and 24 hours 
(Fig. 4.8B) using a light microscope (10x/0.25 PhP objective; Primovert, Zeiss, Germany). The 
cell free area was calculated by tracing along the border of the in vitro wound using Image J 
software (version 6.0, NIH, USA) and the surface area (µm2) of the cell-free gap was 
determined. The percentage gap closure (% gap closure) was calculated using the following 
equation: [(area 0h –area nh) / (area 0h)] x100. 
4.4. Statistical analyses 
Data are presented as mean ± standard error (SE). Statistical analyses were performed using 
Statistica software (version 10, StatSoft, South Africa). One Way ANOVA with Tukey post 
hoc test was used to determine group effects. In cases where data was not normally distributed, 
non-parametric Kruskall Wallis ANOVA with Dunns multiple comparison test was used to 
determine differences between groups. For in vitro experimentation, the non-parametric Mann 
Whitney-U test was used to determine differences between treatment groups and standard 
culture conditions. Factorial ANOVA with Tukey post hoc test was used to determine the effect 
of group vs time. Case-wise Product-Moment correlation analysis was used to determine 
associations between serum cytokine concentrations and changes in the functional capacity of 
ADSCs. Level of significance was accepted at p < 0.05.  
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Chapter 5 
Results 
5.1. PHASE 1: Participant demographics  
A total of forty-seven (n=47) reproductive aged (32 ± 1.1 years) (mean ± SE) females were 
included in the study. These participants were recruited to specifically fit into one of thre e 
groups as described in the inclusion/exclusion criteria (pg. 42). The initial participant grouping 
was as follows: 1) Ten (n=10) healthy lean (BMI ≤ 25 kg/m2, age 25.6 ± 1.5 years), 2) thirty 
(n=30) obese non-diabetic (BMI ≥ 30 kg/m2, age 32.3 ± 2.2 years) and 3) seven (n=7) 
previously diagnosed type 2 diabetic (T2DM) (BMI ≥ 30 kg/m2, age 39.9 ± 1.1 years) patients. 
All participants had a similar socio-economic background and other than a higher rate of 
occasional alcohol consumption in the younger healthy lean participants (70%) compared to 
the other groups (obese 33.3% and T2DM 14.3%) (p < 0.05). No differences were observed in 
the nutritional or lifestyle habits of participants (Table 5.1.1 and Appendix B).  
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Table 5.1.1. Summary of participant characteristics as reported on the medical history, nutritional and 
lifestyle questionnaires.   
Footnote: Data is presented as mean ± SE. Physical activity was rated according to a modified Borg scale: 1 = sedentary; 2 = 
light activity; 3 = moderate activity and 4 = vigorous activity. Sleeping pattern refers to the percentage of participants within each 
group who regularly sleep more than 6 hours at night. Smoking and alcohol consumption refers to the percentage of participants 
in each group who reported the occasional use of these substances. Meals and snacking refer to the average amount of times in a 
day in which participants consumed full meals or snacks. Medication: “=” refers to the number of participants in that particular 
group who reported the use of medication. Statistical analyses: One way ANOVA with Tukey’s post hoc test.  *p < 0.05 indicates 
significant difference between a specific group compared to healthy lean group. #p < 0.05 indicates significant difference between 
groups. Abbr.: BP – blood pressure; ND – not disclosed; Y – yes. 
  
Characteristics  Healthy lean (n=10) Obese (n=30) T2DM (n=7) 
Age 25.6 ± 1.5 32.3 ± 2.2*# 39.9 ± 1.1* 
BMI (kg/m2) 22.1 ± 2.7  37.1 ± 4.6 30.6 ± 3.6  
Lifestyle 
   
Physical activity 2.3 ± 1.1 2.5 ± 0.7 2.86 ± 1.1 
Sleeping pattern (> 6 hrs) 80% 83% 85% 
Smoking  30% 12%* 0%* 
Alcohol consumption  70% 33%* 14%* 
Nutrition 
   
Meals per day 2.6 ± 0.5 2.5 ± 0.7 2.43 ± 0.5 
Snacking in between 1.6 ± 1.2 1.03 ± 1.2 1.42 ± 1.2 
Tea/coffee tsp sugar 1.9 ± 1.3 2.9 ± 1.4 1.7 ± 1.1 
Medication/supplements    
Contraceptives Y = 3 Y = 3 Y = 0 
BP medication - ND = 2 ND = 1 
  
Lisinopril = 1 Accord glimepiride = 2 
   
Hydrochlorothiazide = 2 
   
Gliclazide = 1 
Cholesterol - - Simvastatin = 2 
Diabetic treatment - - Indo metformin = 6 
   
Glucophage =1 
   
Insulin injections = 2 
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5.2. PHASE 2: Metabolic and inflammatory profile of participants 
Following assessment of each participant’s metabolic risk factors (Table 5.2.1), the non-
diabetic obese participants (BMI ≥ 30 kg/m2) (n=30) were further subdivided into healthy 
obese (n=11) (< 3 metabolic risk factors) and metabolic syndrome (n=19) (≥ 3 metabolic risk 
factors) groups. The criteria used for identifying individuals with metabolic syndrome is 
described in Table 5.2.1 and complied with the recommendations of the International Diabetes 
Federation (IDF, 2005).  
 
Table 5.2.1. Metabolic risk factors associated with metabolic syndrome. 
Risk factor Normal physiological values 
Fasting blood glucose (mmol/L) ≤ 5.60 
Systolic BP (mmHg) ≤ 130 
Diastolic BP (mmHg) ≤ 85 
Triglycerides (mmol/L) 1.70 - 2.25 
HDL (mmol/L) 1.04 - 1.55 
LDL (mmol/L) 2.59 - 3.34 
Total cholesterol (mmol/L) ≤ 6.20 
Waist-to-hip ratio ≤ 0.85 
Footnote: Expected normal physiological values that pose no metabolic risk. Participants were classified as having metabolic 
syndrome if (in addition to BMI ≥ 30kg/m2) more than three (>3) of the above metabolic risk factors were abnormal. Criteria used 
according to the International Diabetes Federation’s recommendations (IDF, 2005). Abbr.: BP – blood pressure; HDL – high 
density lipoprotein; LDL – low density lipoprotein.  
Following subdivision of the obese participants based on their metabolic risk, indication of 
dyslipidaemia, the body composition of participants and their inflammatory cytokine profiles 
were compared. 
5.2.1. Metabolic profile 
The metabolic profile of healthy lean (n=10), healthy obese (n=11), obese metabolic syndrome 
(n=19) and T2DM (n=7) participants are represented by Figures 5.2.1 and 5.2.2 (pg. 64). As 
expected, T2DM participants had significantly elevated fasting blood glucose levels (8.8 ± 3.8 
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mmol/L) (p < 0.05) compared to the other groups whom were all within normal physiologica l 
range (< 5.6 mmol/L) (Fig. 5.2.1A). Although the BMI of all the obese participants (healthy 
obese, metabolic syndrome and T2DM) were significantly higher than that of the healthy lean 
group (22.1 ± 0.84 kg/m2), the T2DM participants had a lower BMI (30.6 ± 1.4 kg/m2) 
compared to the metabolic syndrome participants (37.8 ± 1.0 kg/m2) (Fig. 5.2.1B). The waist-
to-hip-ratio was however abnormal (> 0.85) in both the metabolic syndrome and T2DM groups 
(Fig. 5.2.1C). None of the participants had severe hypertension, although blood pressure levels 
were slightly higher in the metabolic syndrome group (systolic 127.7 ± 16.5 mmHg; diastolic 
83 ± 7.9 mmHg) (p < 0.05) compared to that of healthy individuals (Fig. 5.2.1D).  
Participants’ serum was furthermore analysed for total cholesterol, triglyceride, low density 
lipoprotein (LDL) and high density lipoprotein (HDL) levels in order to assess for signs of 
dyslipidaemia. Healthy lean participants tended to have lower total cholesterol (3.81 ± 0.12 
mmol/L), whilst a tendency was observed for increasing levels at the different metabolic stages 
(healthy obese 4.1 ± 0.24 mmol/L; metabolic syndrome 4.5 ± 0.28 mmol/L; T2DM 4.7 ± 0.35 
mmol/L) (Fig. 5.2.2). Participants in the T2DM group had significantly higher triglycer ide 
levels (1.56 ± 0.66 mmol/L) (p < 0.01) compared to the healthy lean (0.58 ± 0.04 mmol/L),  
healthy obese (0.65 ± 0.05 mmol/L) and metabolic syndrome (0.79 ± 0.04 mmol/L) groups. 
Significantly higher levels of LDL were observed in the metabolic syndrome group (3.1 ± 0.9 
mmol/L) (p < 0.05). There were no significant differences in the levels of HDL between the 
different groups (Fig. 5.2.2). Taken together, these results confirmed that our groups are 
representative of different metabolic stages typically expected in disease progression from 
healthy to obese metabolic syndrome and ultimately T2DM.  Thus  validating our model for 
subsequent in vitro experiments utilizing the participant-derived serum.  
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Figure 5.2.1. Metabolic markers. Graphic representation of the average A) fasting blood glucose levels B) BMI, C) waist-to-
hip ratio and D) blood pressure levels in each group. Statistical analyses: One way ANOVA with Tukey’s post hoc test.  *p < 
0.05; **p < 0.01 indicate significant difference between a specific group compared to healthy lean group. # p  < 0.01 indicates 
significant differences between groups. The red line refers to normal healthy physiological values. 
 
 
Figure 5.2.2. Lipid profile. Results of the lipid panel analysis showing total serum levels of cholesterol, LDL, HDL and 
triglyceride levels of participants in the different groups. Statistical analysis: One way ANOVA with Tukey post hoc test. *p < 
0.05 indicates a significant difference between a specific group compared to healthy lean control group. #p < 0.01 indicates 
significant differences between groups. Abbr.: HDL – high density lipoprotein; LDL – low density lipoprotein; T2DM – type 2 
diabetes mellitus. The red line refers to normal healthy physiological values. 
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5.2.2. Body composition and bone mineral density 
The body composition of each participant, with a specific focus on the distribution of fat 
throughout different body regions, were assessed and is presented in Table 5.2.2 as well as 
Figures 5.2.4 and 5.2.5. As expected, the healthy obese (49.3 ± 0.84 %) (mean ± SE) (p < 
0.001) and metabolic syndrome (50.1 ± 0.73 %) (p < 0.01) groups had a significantly greater 
percentage of total body fat compared to the healthy lean group (37.5 ± 2.1 %). In contrast to 
the BMI data for the T2DM group (section 5.2.1, Fig. 5.2.1B), the percentage of total body fat 
in the T2DM group (40.3 ± 2.4 %) did not differ from the healthy lean group. The only 
significant differences in fat distribution between the healthy lean and the T2DM groups were 
observed in the gynoid region (healthy lean 44.0 ± 1.7 %; T2DM 42.0 ± 3.6 %) (p < 0.05).  
The adipose indices did however indicate a higher android-to-gynoid, as well as trunk-to- leg 
fat ratio in the T2DM (1.0 ± 0.04 & 1.1 ± 0.04), healthy obese (0.98 ± 0.02 & 0.93 ± 0.03) and 
metabolic syndrome (0.99 ± 0.02 & 0.97 ± 0.02) groups compared to the healthy lean group 
(0.82 ± 0.04 & 0.77 ± 0.04) (p < 0.01). The metabolic syndrome and T2DM groups also 
displayed a significantly higher (p < 0.05) trunk-to-limb fat mass ratio compared to healthy 
lean participants that was not evident in the healthy obese group (Fig 5.2.4). Taken together, 
the whole body DXA scan demonstrated a normal body composition for healthy lean 
participants, whereas excessive body fat for healthy obese participants was predominantly in 
the subcutaneous regions (pear-shape body) and predominantly in the visceral regions (apple-
shaped body) for the metabolic syndrome and T2DM groups.  
In addition to adipose indices, the DXA scan also provided information regarding each 
participant’s bone mineral density (BMD). There were no significant differences in BMD 
observed between the different groups. However, the metabolic syndrome group showed 
significantly higher T-score (1.1 ± 1.4) and Z-scores (1.4 ± 1.3) (p < 0.05) compared to the 
healthy lean group (0.04 ± 1.2 & 0.05 ± 1.1) (Fig. 5.2.5).  
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Table 5.2.2. Summary of body fat distribution throughout specific body regions .  
  
Footnote: DXA scan results showing total percentage fat in the left (L) and right (R) arms, trunk, left (L) and right (R) legs, 
android and gynoid regions as well as the total percentage of fat in the body. Statistical analysis: Data is presented as mean ± SE.  
*p < 0.05; **p < 0.01; ***p < 0.001 indicates significant differences between a specific group compared to the healthy lean group. 
#p < 0.05 indicates significant difference between a specific group and the T2DM group.  
 
 
 
Figure 5.2.3. Dual energy x-ray absorptiometry (DXA) scans . Representative images of participants in the different 
groups. A) Healthy lean participant. B) Healthy obese participant. C) Metabolic syndrome participant. D) T2DM participant. 
Abbr.: R – region; R1 – left and right arms, R2 – left and right legs, R3 – trunk, R4 – head, R5 – android, R6 – gynoid.  
 
Body region
Healthy lean 
(n=10)
Healthy obese 
(n=11)
 Metabolic 
syndrome (n=19)
T2DM (n=7)
L Arm 38.7 ± 3.5 50.4 ± 1.5*# 52.3 ± 1.3*# 41.5 ± 2.1
R Arm 37.0 ± 3.6 50.8 ± 1.5*# 51.6 ± 1.3*# 42.0 ± 2.5
Trunk 34.4 ± 2.8 49.2 ± 1.3***# 50.7 ± 0.9***# 40.8 ± 2.2
L Leg 44.1 ± 1.8 53.1 ± 0.9*# 52.6 ± 0.6*# 42.5 ± 3.4
R Leg 44.0 ± 1.6 52.7 ± 0.9*# 52.2 ± 0.7*# 42.0 ± 3.4
Android 36.3 ± 3.2 51.9 ± 1.1***# 51.5 ± 1.3***# 41.6 ± 2.9
Gynoid 44.0 ± 1.7 53.0 ± 0.9***# 52.2 ± 0.6***# 42.0 ± 3.6*
Total 37.6 ± 2.1 49.3 ± 0.8***# 50.1 ± 0.7***# 40.3 ± 2.4
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Figure 5.2.4. Adipose indices. DXA scan results of the ratio of fat in the android versus the gynoid regions; the percentage of fat 
in the trunk region versus percentage of fat in the leg region and trunk fat versus limb fat. Statistical analysis: One way ANOVA 
with Tukey post hoc test. **p < 0.01 indicates significant difference between a specific group compared to healthy lean group.  
 
 
Figure 5.2.5. Bone mineral density. T-score refers to BMD values obtained from individual participants when compared to that 
of an average woman in their thirties. Z-score refers to BMD values obtained from individuals in the study, compared to that of 
women within their age range. T- and Z-scores ≥ -1.0 are considered normal for healthy individuals. Statistical analysis: One 
way ANOVA with Tukey post hoc tests. *p < 0.05 indicates significant difference between a specific group compared to the 
healthy lean control group. Abbr.: BMD – bone mineral density; cm2 – centimetre squared; g – grams. 
5.2.3. Inflammatory profile 
The serum circulating levels of pro- (CRP, IL-6, IL-8, TNF-α, IFN-γ, SDF-1α) and anti-
inflammatory (IL-10) cytokines were determined for each participant as indication of their 
overall inflammatory status. Individual variability was high and data are therefore presented as 
box-and-whisker plots in Figures 5.2.6 and 5.2.7 (pg. 68 - 69).  
Significantly higher levels of the C-reactive protein (CRP) were observed in the metabolic 
syndrome group (50.87 ± 24.2 pg/mL) (mean ± SE) (p < 0.05) compared to the healthy lean 
group (6.08 ± 5.03 pg/mL), indicating inflammation in this group. The healthy obese group 
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(29.8 ± 8.78 pg/mL) also showed a tendency towards higher CRP levels, although this was not 
significant (p=0.07) (Figure 5.2.6A). Due to individual variability, no significant differences 
were observed in the circulating levels of pro-inflammatory cytokines interleukins – IL-6, IL-
8, tumour necrosis factor - alpha (TNF-α) and interferon – gamma (IFN-γ), between the 
different groups (Fig. 5.2.6 B-E). Serum levels of SDF-1α were variable, especially in the 
metabolic syndrome (113.7 ± 26.6 pg/mL) and T2DM (139.3 ± 45.7 pg/mL) groups compared 
to the healthy lean (60.55 ± 4.3 pg/mL) and healthy obese (71.86 ± 4.86) groups, but these were 
not significant (Fig. 5.2.6B). 
 
 
 
Figure 5.2.6. Pro-inflammatory cytokines. A) CRP B) IL-6 C) IL-8 D) IFN-γ E) TNF- α and F) SDF1- α levels as determined 
using the Bio-Plex ProTM human cytokine and ELISA assays. Statistical analyses: One-way ANOVA with Tukey’s post hoc test 
and Non-parametric Kruskall Wallis test with Dunns multiple comparison post hoc tests. *p < 0.05 indicates significant difference 
between a specific group compared to healthy lean group. #p < 0.05 indicates significant difference between groups. Abbr.:  CRP 
– C-reactive protein; IFN- γ – interferon gamma; IL – interleukin; SDF-1 α – stromal derived factor-1 alpha; TNF- tumour necrosis 
factor.   
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Circulating levels of the anti-inflammatory cytokine IL-10 were significantly lower in the 
T2DM participants (0.42 ± 0.69 pg/mL) (mean ± SE) (p < 0.05) compared to the healthy lean 
(3.13 ± 0.33 pg/mL), healthy obese (7.10 ± 4.1 pg/mL) and metabolic syndrome (2.93 ± 0.45 
pg/mL) groups.  
 
 
Figure 5.2.7. Serum cytokine levels of IL-10. Statistical analysis: One-way ANOVA with Tukey post hoc test.  
*p < 0.05 indicates significant difference between specific group compared to healthy lean group. #p < 0.05 indicates significant 
difference between groups.   
 
5.3. PHASE 3: The effect of participant derived serum on adipose tissue 
derived mesenchymal stem cell function 
5.3.1. ADSC characterization 
The identity of the human adipose tissue derived mesenchymal stem cells (ADSCs) used in 
subsequent cell culture experiments was confirmed using flow cytometry.  ADSCs (P7) (n=3) 
positively expressed the mesenchymal stem cell surface markers CD90+ (> 99 %), CD105+ (> 
99 %) and CD73+ (> 98 %), whereas only < 41 % of the cell population expressed either 
CD34+ or CD45+ markers (Fig. 5.3.1J-L).  
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Figure 5.3.1. ADSC characterization. A-C) forward and side scatter dot plots displaying the cell population from samples 
ADSC 1, 2 and 3. D-F) dot plots for surface markers CD90+ and CD73+ and the isotype cell population as a negative control 
(ADSC 1 -3). G-H) dot plots for CD90+ and CD105+. J-L) dot plots of CD90+ and PercP stain for negative populations.  
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5.3.2. Cell viability  
In order to assess the effect of participant derived serum on the viability of ADSCs, the MTT 
in vitro toxicology assay was performed. There were no significant differences observed in cell 
viability between the different groups, compared to treatment with standard growth medium 
(SGM) (Fig. 5.3.2). These results suggested that participants’ serum could sustain ADSCs in 
culture, to a similar extent as the SGM.  
 
Figure 5.3.2. Cell viability. Average absorbance levels in the different groups, indicating the measure of cell viability as detected 
using MTT. Abbr.: SGM – standard growth medium, T2DM – type 2 diabetes mellitus.  
5.3.3. Cell proliferation 
The BrdU cell proliferation assay was used to determine the effect of participant derived serum 
on ADSC proliferation capacity. A significant increase in the proliferation rate was observed 
in ADSCs treated with healthy lean participants’ serum (0.160 ± 0.01) (p<0.05) (mean ± SE) 
compared to SGM control (0.145 ± 0.01). This effect was not observed in the obese and T2DM 
groups suggesting the mitogenic effect of patient-derived serum is lost under conditions of 
obesity. 
Additionally, there was a significant correlation observed between the mitogenic response of 
ADSCs and circulating levels of IL-6 in the healthy lean (n=10, r=0.912, p < 0.01) and 
metabolic syndrome (n=19, r=0.616, p < 0.01) groups (Fig 5.3.3B). 
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Figure 5.3.3. Effect of participant derived serum on ADSC proliferation. A) Average absorbance values in the healthy lean, 
healthy obese, metabolic syndrome and T2DM groups, as a measure of the BrdU detected during proliferation of cells. B) 
Relationship between circulating IL-6 and the proliferation of ADSCs. Statistical analysis: One way ANOVA with Tukey and 
Mann-Whitney U post hoc tests and Case-wise Product-Moment correlation analysis. #p < 0.05 indicates significant difference 
between specific groups compared to SGM control. Abbr.: ADSCs – adipose tissue-derived mesenchymal stem cells; SGM – 
standard growth medium.  
5.3.4. Cell migration 
The effect of participant-derived serum on the migration of ADSCs was determined through a 
migration assay. The rate at which cells migrate into an in vitro wound was assessed over a 24 
hour period. Replacement of 10% FBS (SGM) with 20% participant derived serum (refer to 
pg. 55) resulted in the reduced migration rate of ADSCs regardless of metabolic profile (Fig. 
5.3.4). ADSC treatment with SGM resulted in 27.0 ± 3.7 % (mean ± SE) closure of the cell free 
gap after 7 hours, whilst a cell free gap closure of only 11.9 ± 1.5 % with healthy lean 
participants’ serum; 7.9 ± 1.9 % (healthy obese); 10.0 ± 0.9 % (metabolic syndrome) and 10.1 
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± 1.3 % (T2DM) was evident at the same time point (Fig. 5.3.4A). A significant correlation 
was observed between circulating levels of IL-8 and the migration rate of ADSCs (n=19, r = 
0.558, p < 0.05), particularly in the metabolic syndrome group (Fig. 5.3.4B). 
 
 
Figure 5.3.4. Effect of participant derived serum on ADSC migration. A) Percentage area covered by cells after 7 hours. B) 
Relationship between serum circulating IL-8 levels and the migration of ADSCs. C) Graphic representation of the in vitro wound 
area, demonstrating migration of ADSCs into the wound area over 24 hours. Statistical analysis: One way ANOVA with 
Tukey’s post hoc test. #p < 0.05 indicates significant difference in specific group compared to SGM control. Abbr.: ADSCs – 
adipose tissue-derived mesenchymal stem cells; SGM – standard growth medium. 
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Chapter 6 
Discussion 
The detrimental effects of extreme obesity are evident in the growing burden of obesity-
associated non-communicable diseases worldwide (Dalal et al., 2011). The high prevalence of 
obesity in Black South African women (Micklesfield et al., 2013) places them at a high risk of 
developing the metabolic syndrome and obesity-associated inflammatory disorders such as 
T2DM, which when poorly managed, present with numerous co-morbidities (Arababadi et al., 
2010; Dinh et al., 2012; Sun et al., 2016). Adipose tissue-derived mesenchymal stem cells 
(ADSCs) have become the focus of numerous investigations (Zhang et al. 2015; Kaisang et al. 
2017; Wang et al. 2015) for the treatment of diabetes-associated co-morbidities, due to their 
immunomodulatory properties; their ability to differentiate into multiple tissue types as well as 
their sufficient quantities for effective therapy (Ivanova-Todorova et al., 2009). However, 
autologous stem cell therapies have proven unsuccessful. We hypothesised that the 
inflammatory microenvironment observed in obesity and T2DM contributes to the functiona l 
decline of stem /progenitor cells. The exact mechanism and stage during disease progression 
when this occurs is not yet well understood. In this study, we demonstrated for the first time 
that the obesity-associated disruption in the systemic inflammatory balance, may have a 
negative effect on ADSC response, regardless of metabolic profile.  
Participants in this study were characterized according to their metabolic profile, as well as 
results of the health, lifestyle and nutritional questionnaires. Overall, our study population had 
similar lifestyle and nutritional habits, regardless of BMI. This may be attributed to the fact 
that all participants were from similar socio-economic backgrounds (Dubowitz et al., 2008). 
The significantly younger age of women in the healthy lean group potentially explains the high 
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reports of occasional consumption of alcohol and smoking in this group (Peltzer & Pengpid, 
2016; Yi et al., 2017).  Furthermore, the women in the obese groups were significantly older, 
and this was consistent with studies that have reported that older Black women from lower 
socio-economic backgrounds still perceive being overweight as a sign of wealth and good 
health (Draper et al., 2016; Gaston et al., 2011; Mvo et al., 1999; Okop et al., 2016; Okoro et 
al., 2014; von Lengerke et al., 2012). The significantly older age of women in the T2DM group 
was furthermore consistent with studies that have suggested that T2DM develops with 
increasing age (Shai et al., 2006; Frank et al., 2013). This was apparent in that the non-diabetic 
obese participants, who despite their large BMI and excess body fat, were all normoglycaemic , 
with only four (n=4/30) participants reporting the use of hypertension medication.  
Body composition results confirmed the apple shape body type hypothesis in the metabolic 
syndrome and T2DM groups, as observed in the excess abdominal fat; significantly large waist-
to-hip ratio; trunk-to-leg and android-to-gynoid fat ratios. It has previously been shown that 
excess abdominal fat (i.e. the apple shape body type) is a great risk factor for the development 
of metabolic syndrome and ultimately T2DM (Hayes et al., 2013; Goedecke et al., 2009; Peppa 
et al., 2013). The significantly less total body fat in T2DM participants compared to the non-
diabetic obese groups, suggested weight loss in these women. This may be due to metformin 
treatment which has been shown to induce weight loss in diabetic patients independent of diet 
and exercise (Kheirandish et al., 2017; Riediger et al., 2017), with no changes in waist 
circumference (Bray et al., 2012). Moreover, weight loss in T2DM can result from the inability 
of fat and muscle cells to take up glucose, due to insulin resistance, which then leads to the 
excess glycogen breakdown thus resulting in muscle and fat breakdown.  
As expected, the T2DM group had significantly higher fasting glucose levels, which suggested 
poor glycaemic control in these participants. Recent studies have suggested that individua ls 
from lower socio-economic backgrounds tend to not adhere to their recommended treatment, 
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due to lack of information and understanding with regards to their condition (Kokozska, 2017; 
Mendehall & Norris 2015). Increased inflammation was evident in the obese metabolic 
syndrome group as observed with the significantly higher circulating levels of CRP. 
Interestingly, participants in this group had normal average fasting blood glucose levels, higher 
low density lipoprotein (LDL), and a tendency towards lower high density lipoprotein (HDL) 
levels. This suggests that the metabolic syndrome participants were normoglycaemic despite 
the elevated inflammation, and dyslipidaemia. 
Due to the high individual variability within the different groups, no differences were observed 
in circulating pro-inflammatory cytokines (IL-6, IL-8, IFN-γ and TNF-α). However, the lower 
levels of CRP and IL-6 observed in the T2DM group were consistent with reports of reduced 
inflammation due to metformin treatment. Studies have suggested that metformin exerts its 
anti-inflammatory effects through an AMPK-dependent mechanism (Huang et al., 2009; Liu 
et al., 2017; Schuiveling et al., 2017), by inhibiting signalling factors responsible for the 
activation of pro-inflammatory cytokines. Circulating levels of stromal derived factor 1 - alpha 
(SDF1- α), a potent inducer of the mobilization of MSCs from bone marrow into circulat ion, 
were not significantly different in our study population. However, as shown in previous studies, 
there was a tendency towards elevated levels of this chemokine in the T2DM group (Derakshan 
et al., 2012). The significantly low levels of IL-10 in the serum of T2DM participants was 
consistent with previous studies which showed low levels of IL-10 in T2DM patients (Acharya 
et al., 2015; Al-Daghri et al., 2015). This could furthermore explain the high fasting glucose 
levels observed in these participants, since IL-10 has been shown to improve pancreatic β-cell 
function in response to glucose (Pennline et al., 1994).  
Treatment of ADSCs with the healthy lean participants’ serum, demonstrated a mitogenic 
effect. However, this effect was lost in the healthy obese, metabolic syndrome and T2DM 
groups. Furthermore, a significant correlation was observed in the proliferation of ADSCs and 
Stellenbosch University  https://scholar.sun.ac.za
 77 
 
circulating IL-6 levels, particularly in the healthy lean and metabolic syndrome groups, which 
suggested a role for IL-6 in the maintenance of stem cells as previously reported (Pricola et al., 
2009; van de Vyver et al., 2016). Studies have however shown that IL-6 has no proliferat ive 
effect on progenitor cells on its own, but it functions synergistically with multiple other 
cytokines such as oncostatin M (OSM), leukemia inhibitor factor (LIF), stem cell factor (SCF) 
and granulocyte stimulating factor (G-CSF) (Jacobsen et al., 1994; Lee et al., 2006; Miura et 
al., 1993) to promote cell growth. A reduction in the migration rate of ADSCs was observed 
when standard growth medium treatment was replaced with participants’ serum, including that 
of healthy lean participants. Furthermore, there was a correlation between circulating levels of 
IL-8 and the migration rate of ADSCs. This was consistent with studies that suggest IL-8 
independently stimulates migration of MSCs (Braune et al., 2017). Taken together, our study 
demonstrated the association between altered stem cell functionality and a distorted 
inflammatory profile.  
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Chapter 7 
Conclusion/Future Perspective 
One of the earliest evidence of successful stem cell therapy was by Rojas et al. (2005) where 
they made use of bone marrow-derived mesenchymal stem cells (BMSCs) to counteract the 
effect of bleomycin induced lung injury in mice models. Since then, there have been numerous 
reports of successful stem cell therapies in the treatment of diabetes associated complicat ions 
using adipose tissue-derived stem cells (ADSCs). ADSCs have been shown to improve 
pancreatic β-cell function and suppress the dendritic cell differentiation in mice models of 
diabetes, thus improving glucose uptake and inhibiting the release of proinflammatory 
cytokines (Cao et al., 2015; Hao et al., 2013; Ivanova-Todorova et al., 2009; Yeung et al., 
2012). However, autologous stem cell therapies using diabetic patients’ stem cells have proven 
unsuccessful (Shin & Peterson, 2012). In T2DM the multifunctional property of ADSC is 
impaired (Rezaie et al., 2017; Shin & Peterson, 2012). The mechanism and stage at which this 
impairment occurs in MSCs is not yet well understood.  
In our study, we investigated this effect of obesity-associated T2DM on the viability, 
proliferation and migration capacity of ADSCs, using serum derived from healthy lean, healthy 
obese, metabolic syndrome and T2DM women. We demonstrated for the first time, that the 
disruption in the inflammatory balance as a result of obesity, regardless of metabolic syndrome, 
is detrimental to MSC function. Thus, future research should focus on the disease progression 
leading to T2DM, as well as the inflammatory cytokines involved (such as IL-6, IL-8 and SDF-
1α) in order to take preventative measures to curtail MSC impairment.  
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Chapter 8 
Limitations 
Participants’ responses to the health, lifestyle and nutritional questionnaires were all self-
reported which leaves room for misinformation as a way to stay guarded and to give answers 
which they believe are what the investigator wants to hear. The small sample size in this study 
was limiting in that the individual variability in the cytokine levels made it difficult to attain 
statistical significance in some of the cytokines investigated. This was a cross sectional study 
and thus, we could not follow up with participants to observe how long term changes in their 
metabolic and inflammatory profile affects mesenchymal stem cell function, and thus disease 
progression was only investigated at a single time point. Furthermore, the study did not 
measure fasting insulin levels which would have provided further insight into results obtained 
from the metabolic syndrome participants who had normal fasting glucose levels and yet  
displayed increased inflammation.  
Finally, the adipose tissue-derived mesenchymal stem cell line used in the study was an 
immortalized cell line which could possibly skew results since these cells have been 
manipulated for continuous proliferation.  
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Chapter 10 
Appendices 
Appendix A: Health, lifestyle and nutritional questionnaires 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: Stem cell impairment associated with type 2 
diabetes mellitus: Investigating the effect of obesity-associated systemic inflammation on 
mesenchymal stem cell behaviour in three different cohorts of patients.  
 
REFERENCE NUMBER: 
PRINCIPAL INVESTIGATOR: Dr M van de Vyver 
ADDRESS: Room 3050, Clinical building, Department of Medicine, Stellenbosch Univers ity.  
CONTACT NUMBER: 021-938 9263 
 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand. It 
is very important that you are fully satisfied that you clearly understand what this research 
entails and how you could be involved. Also, your participation is entirely voluntary and you 
are free to decline to participate. If you say no, this will not affect you negatively in any way 
whatsoever. You are also free to withdraw from the study at any point, even if you do agree to 
take part. 
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This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
 The World Health Organization indicated that almost half (41%) of South Africa’s 
women are overweight or obese. These obese women have a high risk to develop type 2 
diabetes mellitus. It is also known that the amount and distribution of body fat (hip, waist, legs) 
is not the same in women with black African, Caucasian (white European) or mixed ancestry. 
These differences in fat distribution may also result in differences in the blood levels of 
inflammation biomarkers. This is important, because one of the “side effects” of obesity-linked 
type 2 diabetes, is that the stem cells that are important for wound healing in your body, cannot 
function as they should. This study will investigate if there is a link between the blood 
biomarker levels in women with specific ethnicities and the ability of stem cells to help the 
healing of wounds.  
 Altogether 90 women that are between 18-45 years old will take part in the study (see 
exclusion criteria below). Women from each ethnic population that are healthy and not 
overweight will be in the control group (n=30), women who are obese but not diabetic will be 
in the non-diabetic obese group (n=60) and obese women with type 2 diabetes (n=60) will be 
in the other group.  
 Exclusion criteria (may not take part in study): Males/Females that are older than 45 or 
younger than 18 years; women who are pregnant, or have any infectious diseases or any long-
term illness other than obesity-associated type 2 diabetes mellitus. If you do not know your 
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HIV status, you have the option to be tested and if the test is negative you can take part in the 
study, otherwise you do not have to get tested for HIV and do not have to take part in the study.  
 The study will be done at the Endocrinology Ward A10, Tygerberg Hospital and at the 
Department of Medicine, Stellenbosch University.  
 To see if you can take part in the study, you will be asked to fill out a short lifestyle 
questionnaire (attached at the end of this leaflet) and we will take some body size measurements 
and a qualified clinician will draw blood from your arm.  
 Your weight, height and the size of your hip and waist will be measured so that we can 
calculate your body mass index (BMI). We will also do a type of x-ray scan (DEXA) of your 
whole body that will give us information on where in your body the fat is located. This will be 
done by a qualified research nurse and a DEXA scan specialist. It should not cause you any 
discomfort.  
 The blood sample that will be drawn by a qualified research nurse will consist of a 
single needle prick to your arm where a small amount (25mL) of blood will be collected into 4 
tubes. Two of the tubes will be sent away to Pathcare laboratories, where it will be analysed 
for markers of type 2 diabetes (HbA1c and glucose) and your cholesterol levels (HDL, LDL, 
triglycerides, cholesterol) will be tested. The other 2 tubes will be used for later experiments 
on stem cells in a laboratory.    
 Participants will be subdivided into one of the above mentioned groups. 1) Obese type 
2 diabetic patients (n=20 from each ethic group: Black African, Mixed ancestry and 
Caucasian). 2) Lean healthy control participants  (n=10 from each ethnic group: Black 
African, Mixed ancestry and Caucasian) and 3) Non-diabetic obese participants (n=20 from 
each ethic group: Black African, Mixed ancestry and Caucasian). No further testing or sample 
collection will be needed. The second part of the research will be done in a laboratory, where 
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the blood samples that were collected will be analysed for the levels of inflammatory 
biomarkers and will then be used to treat stem cells.  
 The effect that blood samples collected from control, non-diabetic obese and type 2 
diabetes participants with different ethnicities has on the functions of stem cells will be tested. 
This is important for future patients, since a better understanding of why stem cells ”stop 
working” during type 2 diabetes will help us to identify biomarkers that are “bad” and may 
contribute to the future development of new medicine that are specific for African populations.  
 You will not receive any new medication or new treatment if you take part in this study. 
All the samples that are collected will be stored in a freezer for 5 years after which it will be 
discarded. No other testing will be done and your blood samples will not be used for anything 
else. 
 All the information and data that are collected in this study will be strictly confidentia l 
and will not be shared with anyone other than the researchers involved in the study. You will 
remain completely anonymous and your name will not appear on any of the samples or 
anywhere other than the consent form. 
 
Why have you been invited to participate? 
 You are invited to participate if you are a type 2 diabetic patient visiting the weekly 
clinic at Tygerberg Hospital or if you are a healthy lean women or non-diabetic obese women 
that can fall within the control group. The control group is essential in order to have a “normal” 
response to compare the data of the type 2 diabetes group with. 
 
What will your responsibilities be? 
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 You will only be expected to visit the Endocrinology Ward A10 Tygerberg hospital in 
one day when all the measurements will be taken. If you are interested in receiving feedback 
from the blood samples that were taken, you will be asked to visit the Endocrino logy ward a 
second time, where a medical doctor or research nurse will explain the results to you. 
Otherwise, you can ask that we phone you with the feedback.  
 
Will you benefit from taking part in this research? 
 Your direct benefit from participating in the study will be the feedback you receive 
from the cholesterol tests and life style questionnaire. The research clinician will explain to 
you what it means and if necessary you will be referred to a medical specialist for follow-up. 
You will receive R150 for your time and effort spent to take part in this study.  
 The research will better our understanding of the basic regulation of stem cells and the 
potential of these cells to enhance wound healing. The outcome of the research will enable 
more in depth studies to be performed looking at mechanisms and downstream effects of 
inflammatory biomarkers on stem cells that were identified as “bad”. A better understand ing 
of these processes can contribute to the future development of anti-inflammatory drugs in order 
to improve personalized treatment strategies within the African context. 
 
Are there any risks involved in your taking part in this research? 
 There are no serious risks involved in taking part in this research. You may feel some 
discomfort and slight pain when the blood sample is taken by the nurse. 
 
If you do not agree to take part, what alternatives do you have? 
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 Participation is totally voluntary and you will not be penalized or disadvantaged in any 
way if you decide not to take part.  
 
Who will have access to your medical records? 
 All the information collected will be treated as confidential and your identity will be 
protected. Only the medical doctor, nurse and researcher will have access to your medical 
records and only with your prior permission. If the data is used in a publication all participants 
will remain anonymous.  
 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
 In such an unlikely event of serious injury as a direct result of the study protocol, the 
Division of Endocrinology, Stellenbosch University will offer compensation to the participant 
for any medical fees or other related costs involved for the participant.  
Will you be paid to take part in this study and are there any costs involved? 
There will be no costs involved for you to take part in this study and you will receive R150 for 
your time and effort.  
Is there anything else that you should know or do? 
 You can contact Dr M van de Vyver at Tel: 021-938 9263 if you have any further 
queries or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by the study researcher 
and clinicians. 
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 You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (insert title of study). 
 
I declare that: 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
• I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
Signature of participant     Signature of witness 
Stellenbosch University  https://scholar.sun.ac.za
 102 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign 
the declaration below.) 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
Signature of investigator     Signature of witness 
 
Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
• I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
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• I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
Signature of interpreter     Signature of witness 
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MEDICAL HISTORY AND LIFESTYLE QUESTIONNAIRE 
NURSES DOCUMENTATION AND CHECK LIST FOR THE LIFESTYLE AND 
MEDICAL HISTORY QUESTIONNAIRE 
This document is constructed to ensure that all the relevant information is collected from the 
patients who consent to freely participate in the study (Protocol #N15/07/066).  
All information provided is private and confidential and must be maintained as such. This 
information cannot be shared with any other third parties and can only be accessed by the 
medical practitioners and investigators directly involved in this study.  
Please ensure that all questions are completed on behalf of the patients and that all the 
information provided is accurate. In case of any uncertainty, please ask for assistance from the 
primary investigator (Dr. M van de Vyver, Office phone 021-938-9263).  
 
OVERALL SUMMARY CHECK LIST 
Please check once performed  
 Does the patient fully understand what participation will entail and has she given 
consent to participate in this study 
 Ensure that the patient has completed, signed and dated the Lifestyle and Medical 
Questionnaire 
 Section 1 of this document has been completed 
 Section 2 of this document has been completed 
 Section 3 of this document has been completed 
 Four vials of blood have been drawn, labelled and stored correctly. 
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 A DEXA scan was conducted, within the last year, on the patient. If not please refer 
the patient accordingly. 
 Ensure that this document is attached to the questionnaire completed by the patient 
 
I, __________________________________, acknowledge the accurate collection and 
completion of the above stated tasks.  
HSPCS number: ___________________________ 
Signature:  ___________________________ 
Date:  ___________________________ 
SECTION 1: BASIC PATIENT DETAILS 
Patient number: _____________________________  
Date of Birth:   _____________________________ 
Ethnicity:   African   Caucasian   Mixed Race Ancestry  
Other; if other, please specify: ______________ 
Gender:   Female   Male 
Does the patient have children?   Yes   No 
 
SECTION 2: MEDICAL HISTORY OF PATIENT 
This section is to be completed after the patient has given written consent. The information 
should be obtained from the patients’ clinical file and accurately transposed. If possible, this 
section should be completed in the presence of the patient to ensure accuracy. 
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Current Health States  
Please select one of the following statues that best describes the patient’s current flu and/or 
cold status (this includes conditions such as pneumonia and bronchitis) 
 The patient does not currently have a cold or flu 
 The patient does currently have a cold or flu 
Is the patient currently pregnant?  Yes   No 
 
HIV status  
What is your HIV status?  Positive   Negative    Unknown  
If your HIV status is unknown, would you like to be referred in order to find out? 
 Yes   No 
 
TB status 
What is your current TB status?  Positive   Negative    Unknown  
If your TB status is unknown,  
Do you have any of the following conditions listed below?   Yes   No 
A bad cough that lasts 3 weeks or longer 
Pain in the chest 
Coughing up blood or phlegm 
If your TB status is unknown, would you like to be referred in order to find out? 
 Yes   No 
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Other infectious diseases 
Does the patient suffer from any other infectious disease, other than those described above?   
 Yes   No 
If yes, please specify: _______________________________________________________ 
 
Current Medications 
Please list all prescription medications (drug name and dosage) that the patient is currently 
taking. This information should include all medications taken up to three months prior to this 
current assessment: 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_________ 
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Please consult the patient and list any self-prescribed medications, dietary supplements, or 
vitamins they are currently taking. This list should also include any similar items that have 
been up to three months prior to this assessment: 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_________ 
 
Disease of or related to inflammation  
Does the patient have any broken bones or flesh wounds or injuries?   Yes   No 
Has the patient  
Had a heart attack before?       Yes   No 
Had a stroke before?       Yes   No 
Been diagnosed with arthritis?      Yes   No 
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Been diagnosed with any auto-immune disease?   Yes   No 
If yes, please specify: ______________________________________________ 
Been diagnosed with asthma?      Yes   No 
Been diagnosed with cancer?      Yes   No 
 
Metabolic syndromes  
Has the patient 
Been diagnosed as having undergone menopause?   Yes   No 
Been diagnosed with any hormonal syndrome?    Yes   No 
If yes, please specify: _______________________________________________ 
 
Been diagnosed with type 1 diabetes mellitus?    Yes   No 
 
Been diagnosed with type 2 diabetes mellitus?    Yes   No 
If yes, when was this first diagnosed? __________________________________ 
 
Been diagnosed with gestational diabetes mellitus?   Yes   No 
If yes, when was this diagnosed? _______________________________________ 
 
SECTION 3: BIOLOGICAL PARAMETERS OF THE PATIENT 
Height:   
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Weight: 
Hip Size: 
Waist size: 
 
 
Has the patient been for a dual energy x-ray absorptiometry (DEXA) scan within the last year, 
with no change in relation to current BMI?    
 Yes   No 
If no, please refer accordingly 
 
If the patient was previously diagnosed with type 2 diabetes mellitus? 
 The date of diagnosis: ______________ 
Blood triglyceride levels ______________________________ 
Fasting blood HDL levels ______________________________    
Fasting blood LDL levels ______________________________    
Fasting blood total cholesterol levels____________________    
Fasting blood glucose levels ___________________________    
Blood HbA1c levels __________________________________ 
Systolic blood pressure _______________________________ 
Diastolic blood pressure ______________________________    
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Current parameters to be assessed for the patient, if previously undiagnosed for type 2 diabetes 
mellitus: 
 Blood triglyceride levels ______________________________ 
Fasting blood HDL levels ______________________________    
Fasting blood LDL levels ______________________________    
Fasting blood total cholesterol levels____________________    
Fasting blood glucose levels ___________________________    
Blood HbA1c levels __________________________________ 
Systolic blood pressure _______________________________ 
Diastolic blood pressure ______________________________ 
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PATIENT LIFESTYLE AND MEDICAL HISTORY QUESTIONNAIRE  
This document forms part of the XXX study and covers a range of lifestyle and medical related 
questions which you are asked to completed. You are asked to please answer all the questions 
to the best of your ability, ensuring that all information provided is accurate. If you are unsure 
of what is being asked, please enquire for further assistance and explanation.  
All information that you provide is private and confidential and will be maintained as such. 
This information will not be shared with any other third parties and can only be accessed by 
investigators directly involved in this study.  
BASIC PATIENT DETAILS  
Patient number: _____________________________ (For office use only)  
Date of Birth: _____________________________  
Ethnicity:  
 African  Caucasian  Mixed Race Ancestry  
Other; if other, please specify: ______________  
Gender:  Female  Male  
Do you have children?  Yes  No  
LIFESTYLE SECTION  
Occupation, transportation and physical activity  
Are you employed?  Yes  No  
If yes, how much physical activity is required by your job?  
 None (spend most of the day sitting)  
 Mild activity (walking and lifting light objects)  
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 Highly active (physically demanding)  
From the list below please select the option which best describes your main mode of 
transportation?  
 I mostly make use of a motor vehicle (car, bus, taxi)  
 I mostly make use of a bicycle  
 I mostly walk  
 Other, in this case please explain ____________________________  
Food  
How many meals do you eat a day?  1 or less  1  2  3  4 or more  
From the list below please select the option which matches you’re eating pattern most 
accurately  
 I eat no meat, fish or dairy products  
 I eat no meat  
 I eat a mixture of foods, with very little fruit and vegetables  
 I eat a mixture of foods, including fruit and vegetables  
 I eat a mixture of foods, including chips, take away foods and sweets  
 I eat a special medical diet, in this case please explain ____________________________  
When last did you eat or drink anything? 
_______________________________________________  
Smoking  
Do you smoke?  Yes  No  
If yes, How many cigarettes do you smoke per day? _______________  
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How old were you when you started smoking? ______________  
If no, have you  
 Never smoked  
 Previously smoked but have not smoked for less than one year  
 Previously smoked but not smoked for more than one year  
Alcohol  
From the list below please choose the statement below which best described your average 
alcohol drinking habits in a week. Please remember that 1 unit of alcohol is defined as 1 of 
glass wine, ½ pint of beer or a single measure of spirit.  
 I never drink alcohol  
 I drink between 1 to 3 units per week  
 I drink between 4 and 7 units per week  
 I drink more than 7 units per week  
Recreational drugs  
From the list below please choose the statement below which best described your recreationa l 
drug usage habits. Please remember that this does this include medicines prescribed by a 
medical professional, supplements or vitamins.  
 I never use recreational drugs  
 I use recreational drugs infrequently  
 I use recreational drugs frequently  
MEDICAL HISTORY SECTION  
Stellenbosch University  https://scholar.sun.ac.za
 115 
 
For this section you are asked to provide consent that your medical information may be 
obtained from your clinical file at Tygerberg Academic hospital.  
Please tick this box , sign and date below to indicate that you have given consent that your 
medical information may be accessed for the completion of this section of the questionnaire.  
Signature: _______________________________  
Date: _______________________________ 
 
DIETARY QUESTIONNAIRE 
 
Type of diet:  
A healthy 
meal plan  
 
Diabetic diet   Vegetarian Banting / LCHF 
 OTHER:_______________________________ 
 
Eating Frequency  
Full Meals (not snacks) per 
day? 
1 to 2 times 3 times 3 to 4 times 
 
Eating between meals? Not usually  
Once or 
twice   
More than 3 
times  
 
 
QUALITY OF MEALS & SNACKS  
Healthy meals per week Healthy snacks 
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on most days  only on some days on most days  only on some 
days  
Not-so-Healthy meals per week (e.g. take-aways):  
seldom         often           most days of week     
Luxuries 
seldom         often           most days 
of week     
Usual intake of Fruit:    seldom     often     daily           (Portion/s ____ daily   weekly  
monthly) 
Main meal of day mostly consists of (choose only 1) 
  ± ½ plate starches (including starchy vegetables) with <¼ plate of non-starchy vegetables & 
±¼ plate meat  
  ± ½ plate of non-starchy vegetables with <¼ starches & ±¼ plate meat 
  ± ½ plate of meat (including mince, chicken, fish, etc.) with ±¼ plate of non-starchy 
vegetables & ±¼ starches  
  ± equal portions of meat, starches and non-starchy vegetables  
  ± mainly starches with moderate meat portions; no non-starchy vegetables  
Fat intake: 
The use of oil / margarine / fat in preparation of food:   seldom      often     daily     
Usual amounts:   small    moderate    large/plenty     
Type of margarine:   tub     blocks       low fat    Name:_____________________ 
Estimated amount of margarine per month:     250g        500g    x____ per month 
Type of oil:   sunflower      canola   olive       omega 3&6   other:_________________ 
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Estimated amount of oil per month: size of bottle:  750ml      1,5L      2L    x  _____ per 
month  
Size of household for whom oil/margarine is used: ____ Adults  ______ Children  
Liquid Intake (for purpose of assessing sugar intake via liquids; excluding alcoholic beverages) 
Mostly water: little to no cool drinks & no juice:  YES     NO 
Tea / coffee: mostly without sugar  YES     NO 
     
Explore on usual volume (& 
frequency) 
Juices &/ Normal cool 
drinks (JIVE/COKE/etc.) 
seldom often daily  
Sport / Energy drinks &/or 
Flavoured waters  / Iced 
tea 
seldom often daily  
Tea/Coffee with sugar  seldom often daily 
Tsp sugar / cup:____ Cups per 
day:_____ 
 
  
If  NO, complete 
table below  
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PATIENT DATA 
BASIC PATIENT DETAILS
Patient #:
D.O.B
Ethnicity:
Gender: FEMALE
Age: 18-45 years
INFORMATION OBTAINED FROM PATIENT CLINIC FILE: 
YES/NO Date Comments
Units Date of measurement Criteria for inclusion 
>1.7mmol/L
<1.3mmol/L
>48mmol/L (6.5%)
Systolic >130mmHg; diastolic >85mmHg
DEXA Scan:
YES/NO Date
Current health status:
YES/NO/Unkown Details
Diseases related to inflammation:
MEDICATION: (include all meds in the last 3 months)
Drug Dosage Date prescribed / duration of use
Does the patient have cold/flu symptoms?
Is the patient pregnant?
Does the patient have children?
blood pressure
Note: If measures are more than 3 months old; it needs to be repeated on the new samples collected.
DEXA Scan within previous 6 months?
If NO, refer for new scan
If YES, data obtained?
Comments:
Previous diagnosis for type 1 diabetes?
Previous diagnosis for gestational diabetes?
Previous diagnosis for type 2 diabetes?
Biomarkers 
Self-prescribed /over the counter supplements: 
Prescribed medication: 
HIV status?
TB status?
Any infectious diseases?
Broken bones/ flesh wound?
heart attack?
stroke?
Patient #:  GROUP
arthritis?
auto-immune disease?
asthma?
cancer?
Has the patient undergone menopouse?
HDL
LDL
total cholesterol
blood glucose
HbA1c
tryclycerides
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NEW MEASUREMENTS TAKEN AT TIME OF PATIENT VISIT TO A10: Date
weight
height
hip
waist
>30 kg/m2
SAMPLE COLLECTION AND STORAGE:
2x SST (yellow) serum tubes
2x EDTA (purple) plasma tubes
Calculated BMI
Comments:
Physical activity:  
Indicate 1 - 4 1 Sedentary (spend most of the day sitting)
2 Light activity (general household chores, lifting light objects, heart rate not raised)
3 Moderate activity (walking/cycling at least 10 minutes a day, planned exercise of at least 10 min., heart rate slightly raised)
4 Vigorous activity (walking/cycling for more than 1 hr, lifting heavy objects, heart rate increased on most dasy of week)
Smoking: IF YES
Do you smoke? Cigarettes per day
Age when patient started smoking
IF NO
Never smoked
Stopped smoking less than a year ago
Stopped smoking more than a year ago
Alcohol:
Most accurately describe drinking habits? Never drink alcohol
Ocassional drinker
between 1 and 3 units per week
between 4 and 7 units per week
more than 7 units per week
Recreational Drugs:
Most accurately describe recreational drug use? Never
Use recreational drugs infrequently
Regular use of recreational drugs
Sleeping Pattern:
Average hours of sleep usually less than 6 hours
usually more than 6 hours
Do you work night shifts? YES/NO
About once a week
More than 3 times a week
Frequency
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Appendix B: Participant characteristics 
 
  
Lifestyle Nutritional information 
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Meal composition Luxuries 
Fruit 
intake 
(weekly) 
Use of Oil 
Type of 
Oil 
Type of 
Butter 
Tea/Coffee 
Control Group  
             
1 30 1 1 Y N 2 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 4 often, 
moderate 
Olive Flora, LF None 
2 31 1 0 N Y 2 0 1/2 meat, 1/4 starch, 
1/4 veg. 
Seldom 5 often, small Canola & 
Olive 
Stork, LF seldom, no sugar  
3 20 1 1 Y Y 3 2 1/2 meat, 1/4 starch, 
1/4 veg. 
Seldom 2 seldom, 
moderate 
Sunflower Rama 1 daily, 4 sugars 
4 28 3 0 N Y 2 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 10 seldom, 
moderate 
Canola & 
Olive 
Flora, LF 2-3 daily, 1-2 
sugars 
5 22 4 1 N Y 3 2 1/2 veg, 1/4 meat, 1/4 
starch 
Often 7 daily, moderate Sunflower Stork 1 daily, 3 sugars 
6 31 3 1 Y Y 2 0 1/3 veg, 1/3 starch, 1/3 
meat 
Often 3 often, 
moderate 
Canola   Blossom, LF 3 daily, 2 sugars 
7 29 2 1 N N 3 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 10 daily, moderate Sunflower Rama seldom, 2 sugars 
8 23 2 1 N N 3 3 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 10 seldom, small Olive Blossom, LF 2 daily, 2 sugars 
9 23 3 1 N Y 3 3 1/2 veg, 1/4 meat, 1/4 
starch 
Seldom 2 seldom, small Canola Flora, LF 1 daily, 3 sugars 
10 19 3 1 N Y 3 2 1/2 veg, 1/4 meat, 1/4 
starch 
Seldom 10 seldom, small Canola None seldom, 1 sugar  
Obese Group 
             
11 26 2 0 N N 3 2 1/2 meat, 1/4 starch, 
1/4 veg. 
Seldom 10 daily, moderate Sunflower Sunshine, LF 1 daily, 3 sugars 
12 38 3 1 N N 2 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 3 daily, moderate Sunflower Rama 1 daily, 2 sugars 
13 30 3 1 N N 3 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 10 often, small omega 3&6 Flora, LF 1 daily, 2 sugars 
Continues on next page 
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14 23 2 1 N Y 3 2 1/2 starches, 1/4 meat, 
1/4 veg. 
Often 7 daily, moderate Sunflower Rama 1 daily, 6 sugars 
15 36 3 1 N N 3 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 7 daily, moderate Sunflower Sunshine, LF 3 daily, 3 sugars 
16 34 2 1 N N 2 3 1/2 starch, 1/4 meat, 
1/4 veg. 
Often 2 often, 
moderate 
Sunflower Rama 1 daily, 4 sugars 
17 37 1 1 N N 2 3 1/2 meat, 1/4 starch, 
1/4 veg. 
Often 2 daily, moderate Sunflower Rama 3 daily, 2 sugars 
18 41 2 1 Y Y 2 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 7 daily, small Sunflower Rama 3 daily: 3 sugars 
19 21 2 0 N Y 2 0 1/2 starch, 1/4 meat, 
1/4 veg. 
Seldom 7 often, small Sunflower Sunshine often 
20 23 3 1 N N 4 0 1/2 veg, 1/4 meat, 1/4 
starch 
Seldom 2 often, 
moderate 
Canola   seldom  
21 43 3 0 N N 2 2 1/2 starch, 1/4 meat, 
1/4 veg. 
Seldom 3 daile,moderate Sunflower Rama 2 daily: 2  sugars 
22 23 3 1 N N 3 0 1/2 starch, 1/4 meat, 
1/4 veg. 
Seldom 3 daily, moderate Sunflower Rama 3 daily, 3 sugars 
23 23 3 1 N N 2 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 14 often, small Olive Stork 3 daily, 1 sugar 
24 43 3 1 N N 3 1 1/2 starch, 1/4 meat, 
1/4 veg. 
Seldom 1 daily, moderate Sunflower Sunshine, LF 1 daily, 5 sugars 
25 43 3 1 N N 3 0 1/2 meat, 1/4 starch, 
1/4 veg. 
Often 2 seldom, 
moderate 
Sunflower Stork 2 daily, 4 sugars 
26 35 3 1 N N 2 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 7 daily, moderate Sunflower Sunshine D 2daily, 3 sugars 
27 19 1 1 N Y 2 1 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 0,5 daily, moderate Sunflower None 1 daily, 5 sugars 
28 27 3 1 N N 2 3 1/2 starch, 1/4 meat, 
1/4 veg. 
Often 14 daily, moderate Sunflower Sunshine D 1 daily: 3 sugars 
29 24 2 1 Y Y 2 0 mainly starches, 
moderate meat and no 
vegetables 
Often 2 seldom, plenty Canola - seldom 
30 40 4 0 N N 3 0 banting diet/LCHF Seldom     Coconut/Ol
ive oil 
  1 daily: 0 sugars 
31 45 2 1 N N 4 0 1/2 veg, 1/4 meat, 1/4 
starch 
Seldom 2 daily, moderate Sunflower Rama 1 daily: 2 sugars 
32 26 2 1 N Y 3 3 1/2 starch, 1/4 meat, 
1/4 veg. 
Often 7 daily, moderate Sunflower Sunshine D seldom 
33 30 2 1 Y Y 2 0 1/2 starch, 1/4 meat, 
1/4 veg. 
often 7 often, 
moderate 
      
34 44 1 1 N Y 2 1 1/3 veg, 1/3 starch, 1/3 
meat 
Often   daily, moderate Sunflower   2 daily: 2 sugars 
Continued from previous page 
Continues on next page 
Stellenbosch University  https://scholar.sun.ac.za
 122 
 
35 34 3 0 N N 3 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 7 daily, plenty Sunflower Sunshine, LF None 
36 44 3 1 N N 2 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 2 seldom, small Sunflower Rama 2 daily, 2 sugars 
37 40 2 1 N N 3 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 2 daily, small Sunflower Rama 2 daily, 3 sugars 
38 29 3 1 N Y 2 0 1/2 meat, 1/4 starch, 
1/4 veg. 
Seldom 3 daily, plenty Sunflower Sunshine, LF 1 daily, 5 sugars 
39 40 3 1 N N 3 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 10 seldom, small Sunflower Stork 3 daily: 2 sugars 
40 31 3 1 N Y 1 0 1/2 veg, 1/4 meat, 1/4 
starch 
Seldom 7 seldom, small Sunflower Flora, LF None 
T2DM Group                         
41 39 3 0 N Y 3 2 1/2 veg, 1/4 meat, 1/4 
starch 
Seldom 7 seldom, small Sunflower Rama seldom, 1 sugar 
42 38 4 1 N N 2 2 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 7 daily, moderate Sunflower Rama 2 daily, 2 sugars 
43 43 3 1 N N 2 3 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 14 daily, moderate Sunflower Flora, LF 1 daily, 3 sugars 
44 35 3 1 N N 3 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 10 seldom, 
moderate 
Sunflower Rama seldom, no sugar 
45 42 4 1 N N 2 3 1/3 veg, 1/3 starch, 1/3 
meat 
Often 3 daily, plenty Sunflower Rama 2 daily: 2 sugars 
(rooibos)  
46 39 1 1 N N 2 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 4 daily, moderate Sunflower Rama 1 daily: 3 sugars 
47 43 2 1 N N 3 0 1/3 veg, 1/3 starch, 1/3 
meat 
Seldom 2 daily, moderate Sunflower Blossom, LF seldom, 1 sugar  
Footnote: Raw data from participant completed nutrition and lifestyle questionnaires.  
 
  
Continued from previous page 
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Appendix C: Cell culture consumables 
 
1. Phosphate buffer saline (PBS) 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 were added to 800 mL of distilled water and pH set at 7.4 then filled up to 1 L with distilled water.  
2. Freezing Media 
10 % dimethyl sulphurous oxide (DMSO), 80% DMEM (with 1% penicillin/streptomycin), 10% FBS 
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